

8-11-97  
08/726093  
APS  
CHK'D, AM

1. 5,648,239, Jul. 15, 1997, Human camp-dependent protein kinase inhibitor homolog; Phillip R. Hawkins, et al., 435/69.2, 320.1, 325, 348, 358, 367, 369, 419; 536/23.5 :IMAGE AVAILABLE:

US PAT NO: 5,648,239 :IMAGE AVAILABLE: L3: 1 of 30

ABSTRACT:

The present invention provides a polynucleotide (ipka) which identifies and encodes a novel human cAMP-dependent protein kinase A inhibitor homolog (IPKA). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKA.

2. 5,648,238, Jul. 15, 1997, Human protein kinase C inhibitor homolog; Janice Au-Young, et al., 435/69.2, 252.3, 254.2, 320.1, 325, 348, 419; 536/23.5 :IMAGE AVAILABLE:

US PAT NO: 5,648,238 :IMAGE AVAILABLE: L3: 2 of 30

ABSTRACT:

The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC.

3. 5,641,497, Jun. 24, 1997, Gastrointestinal defensins, cDNA sequences and method for the production and use thereof; Charles L. Bevins, et al., 424/405, 94.6; 435/172.3, 252.3, 320.1; 514/12, 16; 530/224, 350; 536/23.5 :IMAGE AVAILABLE:

US PAT NO: 5,641,497 :IMAGE AVAILABLE: L3: 3 of 30

ABSTRACT:

This invention provides gastrointestinal peptides useful as antimicrobial and anti-inflammatory agents. This invention also provides methods for producing peptides, pharmaceutical compositions containing the gastrointestinal defensin peptides, and methods of use thereof. Methods of diagnosing gastrointestinal disorders are also provided.

4. 5,630,924, May 20, 1997, Compositions, methods and apparatus for ultrafast electroseparation analysis; Martin Fuchs, et al., 204/601, 451, 452, 453, 603, 604 :IMAGE AVAILABLE:

US PAT NO: 5,630,924 :IMAGE AVAILABLE: L3: 4 of 30

ABSTRACT:

Compositions, methods, and apparatus for performing ultrafast binding assays by \*\*capillary\*\* \*\*electrophoresis\*\* or other electroseparation techniques are disclosed. In one embodiment, a first binding partner carries a detectable label and a second binding partner is modified to be highly charged. When used in combination with a sample containing an analyte with which both

binding partners can interact and bind thereto, a three-membered complex is formed. The **\*\*electrophoretic\*\*** mobility difference between the unbound and complex-bound forms of labeled first binding partner is such that electroseparation and subsequent detection of an analyte can be accomplished. The compositions, methods, and apparatus disclosed herein also permit quantitative determination of the concentration of an analyte in a sample.

5. 5,629,152, May 13, 1997, Trisubstituted .beta.-lactams and oligo .beta.-lactamamides; Vasulinga Ravikumar, 435/6, 91.1; 514/44; 536/24.3, 24.5 :IMAGE AVAILABLE:

US PAT NO: 5,629,152 :IMAGE AVAILABLE:

L3: 5 of

30

ABSTRACT:

Novel .beta.-lactam monomers bearing various functional groups are prepared. The novel .beta.-lactam monomers can be joined into oligomeric compounds via standard peptide linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen bonding. The oligomeric compounds are useful as diagnostic and research reagents.

6. 5,608,143, Mar. 4, 1997, External regulation of gene expression; Howard P. Hershey, et al., 800/205; 435/320.1; 536/24.1; 800/250 :IMAGE AVAILABLE:

US PAT NO: 5,608,143 :IMAGE AVAILABLE:

L3: 6 of

30

ABSTRACT:

The preparation and use of nucleic acid promoter fragments derived from several genes from corn, petunia and tobacco which are highly responsive to a number of substituted benzenesulfonamides and related compounds are described. These promoter fragments are useful in creating recombinant DNA constructions comprising nucleic acid sequences encoding any desired gene product operably linked to such promoter fragments which can be utilized to transform plants and bring the expression of the gene product under external chemical control in various tissues of monocotyledonous and dicotyledonous plants.

7. 5,605,839, Feb. 25, 1997, Methods and apparatus for use in sequential chemical reactions; Richard J. Simpson, et al., 436/89; 422/50, 186.04; 436/161, 180 :IMAGE AVAILABLE:

US PAT NO: 5,605,839 :IMAGE AVAILABLE:

L3: 7 of

30

ABSTRACT:

This invention relates to methods and apparatus for carrying out chemical reactions between a plurality of reactants and in particular it is amenable to micro or nano scale operation and to the sequential chemical reactions required during such processes as construction or sequencing of proteins, oligonucleotides and polysaccharides. The present invention further relates to a **\*\*capillary\*\*** liquid chromatography system for high-sensitivity

component separation and microsequencing for use in association with the methods and apparatus herein described.

8. 5,605,798, Feb. 25, 1997, DNA diagnostic based on mass spectrometry; Hubert Koster, 435/6, 91.1, 91.2; 536/25.3, 25.4; 935/77, 78 :IMAGE AVAILABLE:

US PAT NO: 5,605,798 :IMAGE AVAILABLE:

L3: 8 of

30

ABSTRACT:

The invention provides fast and highly accurate mass spectrometer based processes for detecting a particular nucleic acid sequence in a biological sample. Depending on the sequence to be detected, the processes can be used, for example, to diagnose (e.g. prenatally or postnatally) a genetic disease or chromosomal abnormality; a predisposition to a disease or condition (e.g. obesity, arteriosclerosis, cancer), or infection by a pathogenic organism (e.g. virus, bacteria, parasite or fungus).

9. 5,599,668, Feb. 4, 1997, Light scattering optical waveguide method for detecting specific binding events; Donald I. Stimpson, et al., 435/6, 5, 7.1, 7.2, 91.2 :IMAGE AVAILABLE:

US PAT NO: 5,599,668 :IMAGE AVAILABLE:

L3: 9 of

30

ABSTRACT:

A waveguide binding assay method involves detecting the scattering of light directed into the waveguide, the scattering being the result of scattering labels specifically bound to the waveguide within the penetration depth of an evanescent wave. The waveguide may be transparent plastic or glass and the binding is typically by oligonucleotide hybridization or immunological capture. Light scattering labels include colloidal metals or non-metals, including gold, selenium and latex. A light absorbing member consisting of dye or concentrated particles may also be employed to enhance signal. Real-time binding and dissociation can be monitored visually or by video imaging, such as with a CCD camera and frame grabber software. Hybridization mismatches of as few as one base can be distinguished by real-time melting curves.

10. 5,591,825, Jan. 7, 1997, Interleukin 4 signal transducers; Steven L. McKnight, et al., 530/350; 435/6, 69.1; 536/23.1, 23.5 :IMAGE AVAILABLE:

US PAT NO: 5,591,825 :IMAGE AVAILABLE:

L3: 10 of

30

ABSTRACT:

The invention provides methods and compositions for identifying pharmacological agents useful in the diagnosis or treatment of disease associated with the expression of a gene modulated by an interleukin 4 signal transducer and activator of transcription, IL-4 Stat. IL-4 Stat peptides and IL-4 receptor peptides and nucleic acids encoding such peptides find therapeutic uses. The subject compositions include IL-4 Stat and IL-4 receptor proteins, portions thereof, nucleic acids encoding them, and specific antibodies. The disclosed pharmaceutical screening

methods are particularly suited to high-throughput screening where one or more steps are performed by a computer controlled electromechanical robot comprising an axial rotatable arm.

11. 5,583,211, Dec. 10, 1996, Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides; Peter J. Coassin, et al., 536/23.1; 435/6; 521/53, 143; 525/333.7, 340, 375; 530/300, 350; 536/24.3, 25.3, 56, 102, 112, 114, 123.1 :IMAGE AVAILABLE:

US PAT NO: 5,583,211 :IMAGE AVAILABLE: L3: 11 of 30

ABSTRACT:

Disclosed herein are surface activated, organic polymers useful for biopolymer synthesis. Most preferably, aminated polypropylene is used for the synthesis of oligonucleotides thereto, and these devices are most preferably utilized for genetic analysis of patient samples.

12. 5,569,754, Oct. 29, 1996, RNA import elements for transport into mitochondria; R. Sanders Williams, et al., 536/23.5; 435/320.1 :IMAGE AVAILABLE:

US PAT NO: 5,569,754 :IMAGE AVAILABLE: L3: 12 of 30

ABSTRACT:

The invention relates to small RNAs encoded within the nucleus of mammalian cells that specifically import to the mitochondria. The RNAs bind to several nucleolar peptides and thus provide potential carriers for import of biological molecules, including metabolites and proteins, into the mitochondrial compartment. Mitochondrial dysfunction in several maternally inherited human diseases may be correctable employing linkage of mitochondrial import signal to mitochondrial tRNA sequences expressed from nuclear trans-genes without requirement for direct genetic transformation of mitochondria.

13. 5,569,599, Oct. 29, 1996, Keratinase from fervidobacterium pennavorans DSM 7003; Garabed Antranikian, 435/220, 68.1, 252.1, 267, 822 :IMAGE AVAILABLE:

US PAT NO: 5,569,599 :IMAGE AVAILABLE: L3: 13 of 30

ABSTRACT:

An enzyme composition containing keratinase is obtained from Fervidobacterium pennavorans DSM 7003. The composition is capable of degradating keratin-containing substrates such as feathers, hair and horn within a few days at between 50.degree. and 105.degree. C. and at a pH of between 4 and 12 under anaerobic conditions. A pH of 10.5 and a temperature of 70.degree. C. or greater are preferred. Dissolving of the substrate can be at least 50% by weight after 24 hours, and in 1 to 4 days the entire substrate can be dissolved. Pretreatment of the substrate at a temperature of 120.degree. C. or greater is not required.



14. 5,563,255, Oct. 8, 1996, Antisense oligonucleotide modulation of raf gene expression; Brett P. Monia, et al., 536/24.31; 435/6; 536/24.1, 24.5 :IMAGE AVAILABLE:

US PAT NO: 5,563,255 :IMAGE AVAILABLE:  
30

L3: 14 of

ABSTRACT:

Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. In preferred embodiments, the oligonucleotides are targeted to mRNA encoding human c-raf or human A-raf. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of detecting the presence of a raf gene using oligonucleotides of the invention, including methods for specific detection of activated truncated raf. Methods of inhibiting hyperproliferation of cells and methods of treating conditions arising from abnormal raf expression which employ oligonucleotides of the invention are also provided.

15. 5,563,050, Oct. 8, 1996, Antisense oligonucleotides against HSV 1, and their preparation; Anuschirwan Peyman, et al., 435/91.1, 6, 91.33, 172.1, 172.3; 514/44; 536/23.1, 24.5 :IMAGE AVAILABLE:

US PAT NO: 5,563,050 :IMAGE AVAILABLE:  
30

L3: 15 of

ABSTRACT:

The invention relates to novel antisense oligonucleotides having the sequences ##STR1## and their mixtures, homologs or modified forms, against HSV 1.

16. 5,559,209, Sep. 24, 1996, Regulator regions of G proteins; Ikuro Nishimoto, 530/326, 327, 328 :IMAGE AVAILABLE:

US PAT NO: 5,559,209 :IMAGE AVAILABLE:  
30

L3: 16 of

ABSTRACT:

A molecule having a peptide sequence of 80 or fewer amino acid residues containing the amino acid sequence of an anticoupling of any of the G proteins, which molecule is useful for inhibiting activation of the G protein by its G-coupled receptor.

17. 5,554,501, Sep. 10, 1996, Biopolymer synthesis using surface activated biaxially oriented polypropylene; Peter J. Coassin, et al., 435/6; 436/63, 89, 94; 530/334; 536/25.3 :IMAGE AVAILABLE:  
US PAT NO: 5,554,501 :IMAGE AVAILABLE:

L3: 17 of

30

ABSTRACT:

Disclosed herein are surface activated, organic polymers useful for biopolymer synthesis. Most preferably, aminated biaxially oriented polypropylene is used for the synthesis of

oligonucleotides thereto, and these devices are most preferably utilized for genetic analysis of patient samples.

18. 5,547,835, Aug. 20, 1996, DNA sequencing by mass spectrometry; Hubert Koster, 435/6, 91.1, 287.2, 288.7; 436/173; 536/25.3, 25.4; 935/77, 78 :IMAGE AVAILABLE:

US PAT NO: 5,547,835 :IMAGE AVAILABLE:

L3: 18 of

30

ABSTRACT:

The invention describes a new method to sequence DNA. The improvements over the existing DNA sequencing technologies are high speed, high throughput, no **\*\*electrophoresis\*\*** and gel reading artifacts due to the complete absence of an **\*\*electrophoretic\*\*** step, and no costly reagents involving various substitutions with stable isotopes. The invention utilizes the Sanger sequencing strategy and assembles the sequence information by analysis of the nested fragments obtained by base-specific chain termination via their different molecular masses using mass spectrometry, as for example, MALDI or ES mass spectrometry. A further increase in throughput can be obtained by introducing mass-modifications in the oligonucleotide primer, chain-terminating nucleoside triphosphates and/or in the chain-elongating nucleoside triphosphates, as well as using integrated tag sequences which allow multiplexing by hybridization of tag specific probes with mass differentiated molecular weights.

19. 5,532,351, Jul. 2, 1996, Nucleic acid sequences encoding OMGP; Kari Stefansson, 536/23.5; 435/69.1; 536/23.1, 24.31; 935/1, 8, 11, 78 :IMAGE AVAILABLE:

US PAT NO: 5,532,351 :IMAGE AVAILABLE:

L3: 19 of

30

ABSTRACT:

The present invention relates to a nucleic acid segment having a nucleotide sequence coding for oligodendrocyte-myelin glycoprotein (OMgp) which belongs to the CR-LR family of proteins. These molecular weight of the protein is about 120-kd as determined by gel **\*\*electrophoresis\*\***. The protein is capable of being linked to biological membranes through a glycosylphosphatidylinositol lipid intermediate anchor. OMgp is expressed in the central nervous system and is correlated with myelination. This invention also relates to the purified OMgp, which bands at q11.2 of chromosome 17. OMgp maps in the chromosome within 6-kd of a translocation breakpoint t (1;17), which cosegregates with neurofibromatosis in some families. A recombinant vector incorporating the coding sequence for OMgp and a host cell for the vector are disclosed. Other aspects of the invention include disclosed methods for preparing the OMgp protein; the detection of the glycoprotein; as well as nucleic acid segments. Detection methods disclosed include in situ hybridization of the OMgp gene. The invention also relates to kits used to detect the OMgp or the nucleic acid coding for it in samples, for example in clinical samples such as blood. These

kits and methods allow identification of persons, tissues or cells, including gametes, carrying the neurofibromatosis gene. 20. 5,529,792, Jun. 25, 1996, Inhibitors of endothelial cell proliferation; Werner Risau, et al., 424/570, 520, 582; 514/2, 21 :IMAGE AVAILABLE:

US PAT NO: 5,529,792 :IMAGE AVAILABLE: L3: 20 of 30  
ABSTRACT:

In order to isolate an inhibitor of the proliferation of endothelial cells from the tissue of vertebrates the tissue selected as the starting material e.g. embryonic tissue or adult brain tissue from birds or mammals, is centrifuged, homogenized and subsequently the tissue extract is applied to a cation exchanger and the substances which bind to the cation exchanger are subjected to a fractionation, the active fractions are separated by gel filtration chromatography and they are purified by reverse phase HPLC. The new inhibitor obtained in this way is suitable for treating disease states in which an inhibition of **\*\*capillary\*\*** growth is necessary such as for the treatment of tumors, rheumatoid arthritis, diabetic retinopathy and retrolental fibroplasia and for treating wounds in order to regulate the regeneration of blood vessels.

21. 5,527,675, Jun. 18, 1996, Method for degradation and sequencing of polymers which sequentially eliminate terminal residues; James M. Coull, et al., 435/6, 4, 18, 195, 212, 227, 228; 436/63, 86, 94; 530/402; 536/18.7, 25.3; 935/76, 77, 78, 88 :IMAGE AVAILABLE:

US PAT NO: 5,527,675 :IMAGE AVAILABLE: L3: 21 of 30  
ABSTRACT:

A method and apparatus for sequentially degrading at least a portion of a polymer of backbone repeating units, the polymer having a terminal repeating unit comprised of a nucleophile and a backbone carbonyl carbon distant from the nucleophile, comprising the steps of first initiating attack of said nucleophile upon said backbone carbonyl carbon by raising the energy level to activate said nucleophile for said attack. Secondly, forming a ring comprising the terminal repeating unit, thereby simultaneously releasing the ring and generating a shortened polymer having a terminal repeating unit capable of nucleophile attack upon the backbone carbonyl carbon and, lastly, maintaining the reaction conditions necessary for repeating steps a and b until the portion of the polymer desired is degraded. In a related embodiment, polyamide nucleic acid (**\*\*PNA\*\***) sequences can be determined by generating a nested set of polymer fragments, each fragment having N-x repeating units where N is the total number of repeating units in the parent polymer and x is the number of degradation cycles the fragment has been subjected to, and then analyzing the nested set of polymer fragments to determine polymer sequence. An apparatus embodying the method of sequential degradation is also described. Analysis

may be by MALD-TOF.

22. 5,521,289, May 28, 1996, Small organometallic probes; James F. Hainfeld, et al., 530/391.5; 424/178.1, 179.1; 436/546, 547, 548; 530/391.1, 391.3, 391.7, 391.9 :IMAGE AVAILABLE:

US PAT NO: 5,521,289 :IMAGE AVAILABLE: L3: 22 of 30

ABSTRACT:

Small organometallic probes comprise a core of metal atoms bonded to organic moieties. The metal atoms are gold, silver, platinum, palladium, or combinations thereof. In one embodiment, a multifunctional organometallic probe comprises a core of metal atoms surrounded by a shell of organic moieties covalently attached to the metal atoms, a fluorescent molecule, e.g., fluorescein, covalently attached to one of the organic moieties, and a targeting molecule, e.g., an antibody, covalently attached to another of the organic moieties.

23. 5,516,698, May 14, 1996, Methods and apparatus allowing sequential chemical reactions; Geoffrey S. Begg, et al., 436/89; 204/450, 451, 452; 436/180 :IMAGE AVAILABLE:

US PAT NO: 5,516,698 :IMAGE AVAILABLE: L3: 23 of 30

ABSTRACT:

A first reactant is immobilized i.e. in a porous matrix (50), adjacent a sample electrode (46) within a reaction chamber. Energizing of the electrode (46) **\*\*electrophoretically\*\*** attracts a mobile second reactant and/or electrolytically induces appropriate reaction conditions to enhance reaction of the first and second reactants. Polarity reversals between the sample electrode (46) and remote electrodes (38), (42), (44) cause unreacted second reactant and/or by-products to migrate away from the immobilized first reactant. The techniques are useful for sequential chemical reactions such as sequencing or construction of proteins, polysaccharides and nucleic acids where cyclical additions and removals of reactants are required. The techniques are amenable to automated micro and nano scale construction and operation and allow direct **\*\*electrophoretic\*\*** (38) interfacing with chromatographic, HPCE and mass spectrophotometric equipment.

24. 5,466,677, Nov. 14, 1995, Dinucleoside phosphinates and their pharmaceutical compositions; Anthony D. Baxter, et al., 514/44; 536/24.5, 26.2, 26.5 :IMAGE AVAILABLE:

US PAT NO: 5,466,677 :IMAGE AVAILABLE: L3: 24 of 30

ABSTRACT:

A dinucleotide analogue of formula ##STR1## where B.<sup>sup.1</sup> and B.<sup>sup.2</sup> are each independently a monovalent nucleoside base radical;

R.<sup>sup.1</sup> is R.<sup>sup.1</sup>.sub.a or Z;



R.sup.1.sub.a, R.sup.2, R.sup.3 and R.sup.4 are each independently hydrogen, halogen or hydroxy;

R.sup.5 is R.sup.5.sub.a or Z;

R.sup.6 is hydrogen or R.sup.6.sub.a ;

R.sup.7 is hydrogen, alkyl-N,N-dialkylphosphoramidyl or R.sup.7.sub.a, R.sup.8 is R.sup.8.sub.a or Z, or the indicated R.sup.7 O and R.sup.8 together denote an isopropylidenedioxy group;

R.sup.5.sub.a and R.sup.8.sub.a are each independently hydrogen, halogen, hydroxy, --OR.sup.10, --OCOR.sup.10 or silyloxy substituted by three C.sub.1 -C.sub.15 hydrocarbyl groups;

R.sup.6.sub.a and R.sup.7.sub.a are each independently a C.sub.1 -C.sub.10 aliphatic radical, a C.sub.6 -C.sub.15 aromatic radical, a C.sub.7 -C.sub.30 araliphatic radical, --COR.sup.11, --SO.sub.2 R.sup.11 or silyl substituted by three C.sub.1 -C.sub.15 hydrocarbyl groups;

R.sup.9 is hydrogen, a C.sub.1 -C.sub.8 aliphatic radical, a C.sub.3 -C.sub.8 cycloaliphatic radical, a C.sub.6 -C.sub.15 aromatic radical, a C.sub.7 -C.sub.13 araliphatic radical, an alkali metal ion or an ammonium ion;

R.sup.10 and R.sup.11 are each independently a C.sub.1 -C.sub.10 aliphatic radical, a C.sub.3 -C.sub.8 cycloaliphatic radical, a C.sub.6 -C.sub.15 aromatic radical or a C.sub.7 -C.sub.16 araliphatic radical; R.sup.x and R.sup.y are independently hydrogen, halogen, hydroxy, a C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.6 -C.sub.15 aryl, C.sub.7 -C.sub.16 aralkyl, C.sub.1 -C.sub.10 alkoxy, C.sub.2 -C.sub.10 alkenoxy, C.sub.6 -C.sub.10 aryloxy or C.sub.7 -C.sub.16 aralkyloxy group, which is substituted or unsubstituted, or --OCOR.sup.z ;

R.sup.z is a substituted or unsubstituted C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.6 -C.sub.15 aryl or C.sub.7 -C.sub.16 aralkyl group; and Z is C.sub.6 -C.sub.10 aryloxythiocarbonyloxy, the C.sub.6 -C.sub.10 aryl group being substituted or unsubstituted.

25. 5,456,909, Oct. 10, 1995, Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo; Henry C. Marsh, Jr., et al., 424/94.63, 94.64; 435/69.6; 514/8; 530/386 :IMAGE AVAILABLE:

US PAT NO: 5,456,909 :IMAGE AVAILABLE:

L3: 25 of 30

#### ABSTRACT:

The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders involving inflammation and inappropriate complement activation and in thrombotic or shock state conditions. The invention provides novel glycoforms and methods for producing, detecting, enriching and purifying such glycoforms. The invention further provides methods of specifically producing a glycoform by recombinant or chemical means. Preferred embodiments of the invention include sialylated glycoforms and glycoforms with a

pI.ltoreq.5.1 determined by chromatofocusing or with a sialic acid to mannose molar ratio of  $>0.25$ . The glycoforms may be formulated alone in therapeutic compositions or in combination with thrombolytic agents.

26. 5,364,780, Nov. 15, 1994, External regulation of gene expression by inducible promoters; Howard P. Hershey, et al., 435/172.3, 320.1; 536/24.1; 800/205 :IMAGE AVAILABLE:

US PAT NO: 5,364,780 :IMAGE AVAILABLE:

L3: 26 of

30

ABSTRACT:

The preparation and use of nucleic acid promoter fragments derived from several genes from corn, petunia and tobacco which are highly responsive to a number of substituted benzenesulfonamides and related compounds are described. These promoter fragments are useful in creating recombinant DNA constructions comprising nucleic acid sequences encoding any desired gene product operably linked to such promoter fragments which can be utilized to transform plants and bring the expression of the gene product under external chemical control in various tissues of monocotyledonous and dicotyledonous plants.

27. 5,316,935, May 31, 1994, Subtilisin variants suitable for hydrolysis and synthesis in organic media; Frances H. Arnold, et al., 435/222, 68.1, 69.1, 219, 252.3, 320.1; 536/23.2; 935/10, 14, 29, 74 :IMAGE AVAILABLE:

US PAT NO: 5,316,935 :IMAGE AVAILABLE:

L3: 27 of

30

ABSTRACT:

In accordance with the present invention, there are provided novel, modified subtilisin enzyme(s) having improved catalytic activity and/or stability in organic media.

28. 5,187,153, Feb. 16, 1993, Methods of treatment using Alzheimer's amyloid polypeptide derivatives; Barbara Cordell, et al., 514/12; 424/94.64; 514/2; 530/324; 930/250 :IMAGE AVAILABLE:

US PAT NO: 5,187,153 :IMAGE AVAILABLE:

L3: 28 of

30

ABSTRACT:

Pharmaceutical compositions containing a 57 amino acid protease inhibitor and uses for those compositions are taught. The protease inhibitor is referred to as A4i which is associated with Alzheimer's disease. In addition to the A4i protease, other analogs are taught as are pharmaceutical compositions containing such analogs and their uses in treating a variety of abnormalities associated with Kunitz-type basic protease inhibitors. For example, it has been found that pharmaceutical compositions containing A4i protease and analogs thereof inhibit plasmin and tryptase, and also inhibit pancreatic trypsin, alpha-chymotrypsin, tissue kallikrein and serum kallikrein. In that certain diseases are associated with a general release of

proteases such as trypsin, chymotrypsin and elastase into the circulatory system pharmaceutical compositions containing A4i and analogs thereof can be used in the management of such diseases.

29. 5,157,019, Oct. 20, 1992, Serine protease inhibitors; George I. Glover, et al., 514/12, 13, 14, 15; 530/324, 325, 326, 327 :IMAGE AVAILABLE:

US PAT NO: 5,157,019 :IMAGE AVAILABLE: L3: 29 of 30

ABSTRACT:

Novel peptides which exhibit inhibitory activity toward serine proteases and methods for preparing and using same are disclosed. In one aspect, the present invention provides peptides comprising a generic inhibitory core having a functional site recognition sequence fused to the N-terminus. The functional site recognition sequence is adapted to provide enhanced selectivity and/or potency for a target protease.

30. 5,017,489, May 21, 1991, Cytotoxic T lymphocyte serine esterase and method for stimulation and inhibition; Mark S. Pasternack, et al., 435/196; 424/146.1, 158.1; 435/212, 213, 226; 530/388.26, 388.75, 389.1, 389.6 :IMAGE AVAILABLE:

US PAT NO: 5,017,489 :IMAGE AVAILABLE: L3: 30 of 30

ABSTRACT:

Antibodies, nucleic acid sequences, and methods for inhibition of lysis for a novel serine esterase produced by both murine and human cytotoxic T lymphocytes. The serine esterase has an apparent molecular weight of approximately 28,000-31,000, as determined by SDS gel \*\*electrophoresis\*\* under reducing conditions, and trypsin-like activity. Inhibition of the esterase correlates with inhibition of the cells' cytolytic activity. Specific inhibition of the serine esterase is useful as a method for immunosuppression as well as for the inhibition of cytolytic activity of T lymphocytes, both in vivo and in vitro. The genes encoding the murine and human serine esterase are homologous.

(FILE 'USPAT' ENTERED AT 19:47:25 ON 11 AUG 1997)

L1 2176 S CAPILLAR? AND ELECTROPHOR?  
L2 988 S PNA OR PEPTIDE(2W)NUCLEIC  
L3 30 S L1 AND L2

6/3/1 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08474774 96082167

Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Ravon DM; Citarella F; Lubbers YT; Pascucci B; Hack CE

Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.

Blood (UNITED STATES) Dec 1 1995, 86 (11) p4134-43, ISSN 0006-4971 Journal Code: A8G

Languages: ENGLISH

Document type: JOURNAL ARTICLE

6/3/2 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08194810 95199261

Isolation of active genes containing CAG repeats by DNA strand invasion by a peptide nucleic acid.

Boffa LC; Carpaneto EM; Allfrey VG

Istituto Nazionale per la Ricerca sul Cancro IST, Genoa, Italy.

Proc Natl Acad Sci U S A (UNITED STATES) Mar 14 1995, 92 (6) p1901-5, ISSN 0027-8424 Journal Code: PV3

Contract/Grant No.: CA14908, CA, NCI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

6/3/3 (Item 3 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

07753075 94144833

Characterization of antisense binding properties of peptide nucleic acids by capillary gel electrophoresis.

Rose DJ

Bioanalytical and Structural Chemistry Department, Glaxo Research Institute, Research Triangle Park, North Carolina 27709.

Anal Chem (UNITED STATES) Dec 15 1993, 65 (24) p3545-9, ISSN 0003-2700 Journal Code: 4NR

Languages: ENGLISH

Document type: JOURNAL ARTICLE

6/3/4 (Item 4 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08/726093  
DIAL.  
5-26-97  
CHK'D  
AM



07047926 91214546

Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract.

Radtke KP; Wenz KH; Heimbürger N

Forschungslaboratorien der Behringwerke AG, Marburg/Lahn.  
Biol Chem Hoppe Seyler (GERMANY) Dec 1990, 371 (12)  
p1119-27, ISSN 0177-3593 Journal Code: AHC

Languages: ENGLISH

Document type: JOURNAL ARTICLE

6/3/5 (Item 1 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00716775

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Method for detecting urinary tumor associated antigens.

Nachweismethode für Harnkarzinom-assoziierte Antigene.  
Procédé de dosage d'antigènes associées au cancer des voies urinaires. PATENT ASSIGNEE:

MORTON, Donald L., (1373120), 15054 Corona del Mar, Pacific Palisades, CA 90272, (US), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

GUPTA, Rishab K., (1373130), 7118 Costello avenue, Van Nuys, CA 91405, (US), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

EUHUS, David M., (1373140), 7038 Ramsgate Place, Los Angeles, CA 90045, (US), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

MORTON, Donald L., 15054 Corona del Mar, Pacific Palisades, CA 90272, (US)

GUPTA, Rishab K., 7118 Costello avenue, Van Nuys, CA 91405, (US)

EUHUS, David M., 7038 Ramsgate Place, Los Angeles, CA 90045, (US) LEGAL REPRESENTATIVE:

Dost, Wolfgang, Dr.rer.nat., Dipl.-Chem. et al (3042), Patent- und Rechtsanwälte Bardehle . Pagenberg . Dost . Altenburg . Frohwitter . Geissler & Partner Postfach 86 06 20, D-81633

München, (DE) PATENT (CC, No, Kind, Date): EP 678744 A2 951025 (Basic) EP 678744 A3 951213

APPLICATION (CC, No, Date): EP 95104918 901031;

PRIORITY (CC, No, Date): US 431533 891103

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE INTERNATIONAL PATENT CLASS: G01N-033/574;

G01N-033/564;

ABSTRACT WORD COUNT: 65

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	260

SPEC A	(English)	EPAB95	16338
Total word count - document A			16598
Total word count - document B			0
Total word count - documents A + B			16598

6/3/6 (Item 2 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00711562

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* Electrochemiluminescent rhenium moieties and methods  
 of production. Elektrochemiluminescente Rhenium-Fraktionen und  
 Verfahren zur Herstellung. Fractions de rhenium  
 electrochimiluminescentes et procedes de production. PATENT

ASSIGNEE:

IGEN, INC., (388191), 1530 East Jefferson Street, Rockville, MD  
 20852, (US), (applicant designated states:

AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE) INVENTOR:

Massey, Richard J., 5 Valerian Court, Rockville, MD 20852, (US)

Leland, Jonathan K., 384 N. Summit Avenue, Gaithersburg, MD

20877, (US) Powell, Michael J., 5 War Admiral Way,

Gaithersburg, MD 20877, (US) Poonian, Mohindar S., 224 High

Timber Court, Gaithersburg, MD 20879, (US) Dressick, Walter J.,

18215 Mulberry Court, Gaithersburg, MD 20877, (US) Hino, Janel

K., 2020 North Calvert St., Arlington, VA 22201, (US) Della

Ciana, Leopoldo, 18215 Mulberry Court, Gaithersburg, MD 20877,

(US) LEGAL REPRESENTATIVE:

Smaggasgale, Gillian Helen et al (76891), Mathys & Squire, 100  
 Grays Inn Road, London WC1X 8AL, (GB)

PATENT (CC, No, Kind, Date): EP 674176 A1 950927 (Basic)

APPLICATION (CC, No, Date): EP 95201320 881104;

PRIORITY (CC, No, Date): US 117017 871104

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: G01N-033/533; C07F-013/00;

C07D-473/08; C07D-213/89; C07D-221/12; C07D-401/04;

C07D-401/14; C07D-487/12; C12Q-001/02; C12Q-001/70;

ABSTRACT WORD COUNT: 253

LANGUAGE (Publication,Procedural,Application): English; English;  
 English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	1777
SPEC A	(English)	EPAB95	19156
Total word count - document A			20933
Total word count - document B			0
Total word count - documents A + B			20933

6/3/7 (Item 3 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00686134

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Allergenic polypeptide from Japanese cedar pollen and  
dna encoding it. Allergenisches Polypeptid von japanischen  
Zederpollen und diese kodierende DNA.  
Polypeptide allergenique provenant du pollen du cedre  
Japonais et DNA encodant celui-ci.

PATENT ASSIGNEE:

KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO,  
(792440), 2-3, 1-chome, Shimoishii, Okayama-shi Okayama,  
(JP), (applicant designated states: DE;FR;GB)

INVENTOR:

Namba, Motoshi, 614-23, Shimo, Seto-cho, Akaiwa-gun, Okayama,  
(JP) Torigoe, Kakuji, 1343-5, Fujito, Fujito-machi,  
Kurashiki-shi, Okayama, (JP)

Kurimoto, Masashi, 7-25, 2-chome, Gakunan-cho, Okayama-shi,  
Okayama, (JP) LEGAL REPRESENTATIVE:

Daniels, Jeffrey Nicholas et al (69921), Page White & Farrer 54  
Doughty Street, London WC1N 2LS, (GB)

PATENT (CC, No, Kind, Date): EP 655500 A1 950531 (Basic)

APPLICATION (CC, No, Date): EP 94308117 941103;

PRIORITY (CC, No, Date): JP 93299151 931105; JP 93344596 931220;

JP 93346814 931227

DESIGNATED STATES: DE; FR; GB

INTERNATIONAL PATENT CLASS: C12N-015/29; C07K-014/415;

A61K-039/36; ABSTRACT WORD COUNT: 92

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	918
SPEC A	(English)	EPAB95	10877
Total word count - document A			11795
Total word count - document B			0
Total word count - documents A + B			11795

6/3/8 (Item 4 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00676981

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Tissue inhibitor of metalloproteinase type three  
(TIMP-3). Gewebeinhibitor fur Metalloproteasen Type 3 (TIMP-3).  
Inhibiteur de metalloproteases d'origine tissulaire du type 3  
(TIMP-3). PATENT ASSIGNEE:

AMGEN INC., (923233), Amgen Center, 1840 Dehavilland Drive,  
Thousand Oaks, CA 91320-1789, (US), (applicant designated  
states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

Silbiger, Scott M, 21520 Burbank Boulevard No.114, Woodland  
Hills, California 91367, (US)

Koski, Raymond A., 7 Meeting House Lane, Old Lyme Road,

Connecticut 06371 , (US)

LEGAL REPRESENTATIVE:

Vossius, Volker, Dr. et al (12524), Dr. Volker Vossius  
Patentanwaltskanzlei - Rechtsanwaltskanzlei Holbeinstrasse 5,  
D-81679 Munchen, (DE)  
PATENT (CC, No, Kind, Date): EP 648838 A1 950419 (Basic)  
APPLICATION (CC, No, Date): EP 94115578 941004;  
PRIORITY (CC, No, Date): US 134231 931006  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT;  
LI; LU; MC; NL; PT; SE  
INTERNATIONAL PATENT CLASS: C12N-015/15; C07K-014/81;  
C12N-001/21; C12N-005/10; A61K-048/00; A61K-038/57;  
A61K-038/43; A61K-038/17; A61K-038/48; C07K-016/38;  
ABSTRACT WORD COUNT: 73

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	1536
SPEC A	(English)	EPAB95	13884
Total word count - document A			15420
Total word count - document B			0
Total word count - documents A + B			15420

6/3/9 (Item 5 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00665576

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Preparation and screening of highly diverse peptide  
libraries for binding activity.  
Herstellung und Auswahlverfahren von hochunterschiedlichen  
Peptidbanken mit Beziehung zur Bindungsfahigkeit.  
Preparation et triage de librairie peptidiques qui presentent  
une haute diversification pour en depister la capacite de  
former une fixation. PATENT ASSIGNEE:

INTERPHARM LABORATORIES LTD., (897900), Science Based  
Industrial Park Kiryat Weizmann, Ness-Ziona 76110, (IL),  
(applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)  
INVENTOR:

Hadas, Eran, 13/2 Shaar HaGolan Street, Kiryat Ganim, Rishon  
LeZion, (IL) Hornik, Vered, 5/16 Harduf Street Mailbox  
No.13613, Rehovot, (IL) LEGAL REPRESENTATIVE:

VOSSIUS & PARTNER (100314), Siebertstrasse 4, D-81675 Munchen,  
(DE) PATENT (CC, No, Kind, Date): EP 639584 A1 950222 (Basic)  
APPLICATION (CC, No, Date): EP 94109577 940621;  
PRIORITY (CC, No, Date): IL 10610693 930622  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT;  
LI; LU; MC; NL; PT; SE  
INTERNATIONAL PATENT CLASS: C07K-001/04; C07H-021/00;  
C07H-013/04; G01N-033/68;



ABSTRACT WORD COUNT: 32

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	1185
SPEC A	(English)	EPAB95	23768
Total word count - document A			24953
Total word count - document B			0
Total word count - documents A + B			24953

6/3/10 (Item 6 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00656474

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* -g(a)-1,3-FUCOSYLTRANSFERASE.

-G(A)-1,3-FUCOSYLTRANSFERASE.

-g(a)-1,3-FUCOSYLTRANSFERASE.

PATENT ASSIGNEE:

KYOWA HAKKO KOGYO CO., LTD., (229066), 6-1, Ohtemachi 1-chome,  
Chiyoda-ku Tokyo 100, (JP), (applicant designated states:  
DE;FR;GB;IT) INVENTOR:

SASAKI, Katsutoshi, 1171-3-201, Honmachida, Machida-shi, Tokyo  
194, (JP) KURATA, Kazumi, 3-14-9, Mirokuji, Fujisawa-shi,  
Kanagawa 251, (JP) HANAI, Nobuo, 7-9-15, Ohnodai,  
Sagamihara-shi, Kanagawa 229, (JP) NISHI, Tatsunari, 39-15,  
Higashimine-machi, Ohta-ku, Tokyo 145, (JP) LEGAL REPRESENTATIVE:  
Kinzebach, Werner, Dr. et al (6468), Patentanwalte Reitstotter,  
Kinzebach und Partner Postfach 86 06 49, D-81633 Munchen,  
(DE)

PATENT (CC, No, Kind, Date): EP 643132 A1 950315 (Basic)  
WO 9423021 941013

APPLICATION (CC, No, Date): EP 94910547 940328; WO 94JP496  
940328 PRIORITY (CC, No, Date): JP 9369016 930329

DESIGNATED STATES: DE; FR; GB; IT  
INTERNATIONAL PATENT CLASS: C12N-009/10;

ABSTRACT WORD COUNT: 74

LANGUAGE (Publication,Procedural,Application): English; English;  
Japanese FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	384
SPEC A	(English)	EPAB95	27443
Total word count - document A			27827
Total word count - document B			0
Total word count - documents A + B			27827

6/3/11 (Item 7 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00633041

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Dinucleotide and oligonucleotide analogues.  
Dinukleotid und Oligonukleotid analog.  
Analogues des di- et oligonucleotides.

PATENT ASSIGNEE:

CIBA-GEIGY AG, (201300), Klybeckstrasse 141, CH-4002 Basel,  
(CH), (applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Baxter, Anthony David, 52 Lime Avenue, Leftwich Green,  
Northwich, Cheshire, (GB)  
Baylis, Eric Keith, 18 Abbey Grove,, Stockport, Cheshire, (GB)  
Collingwood, Stephen Paul, 39 Rosewood, The Hoskers,  
Westhoughton, Bolton, (GB)  
Taylor, Roger John, 14 Stuart Road, Stretford, Manchester, (GB)  
De Mesmaeker, Alain, Ueligasse 31, 4447 Kanerkinden, (CH)  
Schmit, Chantal, Hasenmattstrasse 5, 4059 Basle, (CH)

LEGAL REPRESENTATIVE:

Sharman, Thomas et al (35752), CIBA-GEIGY PLC. Patent  
Department, Central Research, Hulley Road, Macclesfield,  
Cheshire SK10 2NX, (GB) PATENT (CC, No, Kind, Date): EP 614907  
A1 940914 (Basic) APPLICATION (CC, No, Date): EP 94301443  
940301;

PRIORITY (CC, No, Date): GB 9304618 930306

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IE; IT; LI;  
LU; NL; PT; SE

INTERNATIONAL PATENT CLASS: C07H-021/00; C07H-019/04;  
A61K-031/70; ABSTRACT WORD COUNT: 370

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF2	2132
SPEC A	(English)	EPABF2	21174
Total word count - document A			23306
Total word count - document B			0
Total word count - documents A + B			23306

6/3/12 (Item 8 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00628258

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Composition for use in an assay method utilizing  
polynucleotide sequences. Zusammensetzung zur Anwendung in  
einem Bestimmungsverfahren unter Verwendung von  
Polynukleotidsequenzen.  
Composition pour l'utilisation dans un procede de test  
utilisant des sequences polynucleotidiques.

PATENT ASSIGNEE:

ENZO BIOCHEM, INC., (502800), 325 Hudson Street, New York, N.Y.

10013, (US), (applicant designated states:  
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE) INVENTOR:  
Pergolizzi, Robert G., 375 New Bridge Road, New Milford, New  
York, (US) Stavrianopoulos, Jannis G., 99 South Clinton Avenue  
#11D, Bayshore, NY 11706, (US)

Rabbani, Elazar, 69 Fifth Avenue, New York, New York, (US)  
Engelhardt, Dean L., 173 Riverside Drive, New York, New York,  
(US) Kline, Stan, 235 Lincoln Place, Brooklyn, New York, (US)  
LEGAL REPRESENTATIVE:

VOSSIUS & PARTNER (100311), Postfach 86 07 67, D-81634 Munchen,  
(DE) PATENT (CC, No, Kind, Date): EP 611828 A1 940824 (Basic)  
APPLICATION (CC, No, Date): EP 94102973 840504;  
PRIORITY (CC, No, Date): US 491929 830505  
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE  
INTERNATIONAL PATENT CLASS: C12Q-001/68; G01N-033/58;  
ABSTRACT WORD COUNT: 93

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF2	919
SPEC A	(English)	EPABF2	13924
Total word count - document A			14843
Total word count - document B			0
Total word count - documents A + B			14843

6/3/13 (Item 9 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00601445

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Dictyostelium dipeptidylaminopeptidase.  
Dipeptidylaminopeptidase von Dictyostelium.  
Dipeptidylaminopeptidase de dictyostelium.

PATENT ASSIGNEE:

ELI LILLY AND COMPANY, (204942), Lilly Corporate Center,  
Indianapolis Indiana 46285, (US), (applicant designated  
states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Atkinson, Paul Robert, 3381 West 48th Street, Indianapolis,  
Indiana 46208, (US)

Hilton, Matthew Dale, 5463 Deer Creek Avenue, Indianapolis,  
Indiana 46254, (US)

Lambooy, Peter Karl, 8269 Castle Ridge Lane, Indianapolis,  
Indiana 46256, (US)

LEGAL REPRESENTATIVE:

Hudson, Christopher Mark et al (32091), Erl Wood Manor,  
Windlesham Surrey GU20 6PH, (GB)

PATENT (CC, No, Kind, Date): EP 595476 A2 940504 (Basic)  
EP 595476 A3 940706

APPLICATION (CC, No, Date): EP 93307746 930929;

PRIORITY (CC, No, Date): US 955539 921001  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT;  
LI; LU; NL; PT; SE  
INTERNATIONAL PATENT CLASS: C12N-009/58; C12P-021/06;  
ABSTRACT WORD COUNT: 93

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF2	247
SPEC A	(English)	EPABF2	5132
Total word count - document A			5379
Total word count - document B			0
Total word count - documents A + B			5379

6/3/14 (Item 10 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00599372

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Human nucleic acid fragments isolated from brain,  
adrenal tissue, placenta or bone marrow and their use.  
Menschliche Nukleinsäure, Fragmente vom Hirn, Adrenalgewebe,  
Plazenta oder Knochenmark isoliert und deren Verwendung.  
Fragments d'acids nucleiques humains isolés de cerveau, de  
tissu adréno, placenta et moelle osseuse et leurs  
utilisations.

PATENT ASSIGNEE:

MEDICAL RESEARCH COUNCIL, (791450), 20 Park Crescent, London  
W1N 4AL, (GB), (applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

Sibson, David Ross, 37, Grimsdells Lane, Amersham,, Bucks, HP6  
6HF, (GB) Hadfield, Kathryn Mary, 5, Carlisle Terrace, St.  
Ives, Huntingdon, Cambs, PE17 4PQ, (GB)  
Gross, Jacqueline, 47, Boxmoor Road,, Kenton, Middlesex HA3  
8LH, (GB) Howells, David, 77, Puttocks Drive, Welham Green,  
Harfield, Herts, AL9 7LW, (GB)  
Starkey, Michael, 27, Creasey Close,, Abbots Langley, Herts.  
WO5 0HS, (GB)

Kelly, Maria, 24A Oxford Road,, Ealing, London W5 3ST, (GB)  
Shaw, Diana, 342 Glacier Hall, University of Calgary, 2500  
University Drive NW, Calgary, Alberta T2N 1N4, (CA)

LEGAL REPRESENTATIVE:

Bizley, Richard Edward (28352), HEPWORTH LAWRENCE BRYER &  
BIZLEY 2nd Floor Gate House South West Gate, Harlow Essex  
CM20 1JN, (GB) PATENT (CC, No, Kind, Date): EP 587279 A1  
940316 (Basic) APPLICATION (CC, No, Date): EP 93305451 930713;  
PRIORITY (CC, No, Date): GB 9214857 920713  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT;  
LI; LU; MC; NL; PT; SE  
INTERNATIONAL PATENT CLASS: C12N-015/11; C12N-015/62;



C12P-021/08; C07K-015/28; C12Q-001/68;  
ABSTRACT WORD COUNT: 68

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF2	540
SPEC A	(English)	EPABF2	11064
Total word count - document A			11604
Total word count - document B			0
Total word count - documents A + B			11604

6/3/15 (Item 11 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00586612

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Angiotensin II type-1 receptor and its production.  
Angiotensin-II Typ-1 Rezeptor und dessen Herstellung.  
Recepteur de l'angiotensine II du type I et sa production. PATENT  
ASSIGNEE:

TAKEDA CHEMICAL INDUSTRIES, LTD., (204706), 1-1, Doshomachi  
4-chome, Chuo-ku, Osaka 541, (JP), (applicant designated  
states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Fujisawa, Yukio, 1-31-104, Mikagenakamachi 4-chome,  
Higashinada-ku, Kobe, Hyogo 658, (JP)  
Kuroda, Shun'ichi, 1-1-407-305, Nakaochiai 1-chome, Suma-ku,  
Kobe, Hyogo 654-01, (JP)  
Konishi, Hiroaki, 5-18, Wakazono-cho, Ibaraki, Osaka 567, (JP)

LEGAL REPRESENTATIVE:

Keller, Gunter, Dr. et al (59792), Lederer, Keller & Riederer  
Patentanwälte Prinzregentenstrasse 16, D-80538 Munchen, (DE)  
PATENT (CC, No, Kind, Date): EP 585520 A1 940309 (Basic)  
APPLICATION (CC, No, Date): EP 93105758 930407;  
PRIORITY (CC, No, Date): JP 9285445 920407; JP 92101393 920421;  
JP 9327835 930217

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT;  
LI; LU; NL; PT; SE

INTERNATIONAL PATENT CLASS: C07K-013/00; C12N-015/62;

ABSTRACT WORD COUNT: 49

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF2	428
SPEC A	(English)	EPABF2	7969
Total word count - document A			8397
Total word count - document B			0
Total word count - documents A + B			8397

6/3/16 (Item 12 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00582556

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* CAUSATIVE AGENT OF THE MYSTERY SWINE DISEASE,  
VACCINE COMPOSITIONS AND DIAGNOSTIC KITS.

ERREGER DER MYSTERIOSEN  
SCHWEINEKRANKHEIT, IMPFSTOFF-ZUSAMMENSETZUNGEN UND DIAGNOSE  
KITS.

AGENT PROVOCATEUR DU SYNDROME RESPIRATOIRE ET REPRODUCTIF  
DU PORC, COMPOSITIONS DE VACCINS ET KITS DE DIAGNOSTIC.

PATENT ASSIGNEE:

STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT, (1590590),  
Edelhertweg 15, NL-8219 PH Lelystad, (NL), (applicant  
designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;MC;NL;SE)

INVENTOR:

WENSVOORT, Gert, Dorpsstraat 29, NL-7971 CP Havelte, (NL)  
TERPSTRA, Catharinus, Boeier 02-94, NL-8242 CC Lelystad, (NL)  
POL, Joannes, Maria, Anthonis, Jol 30-05, NL-8243 HA Lelystad,  
(NL) MOORMANN, Robertus, Jacobus, Maria, De Telgang 12, NL-8252  
EH Dronten, (NL)

MEULENBERG, Johanna, Jacoba, Maria, Potgieterstraat 17 II,  
NL-1053 XP Amsterdam, (NL)

LEGAL REPRESENTATIVE:

Smulders, Theodorus A.H.J., Ir. et al (21191), Vereenigde  
Octrooibureaux Nieuwe Parklaan 97, NL-2587 BN 's-Gravenhage,  
(NL)

PATENT (CC, No, Kind, Date): EP 587780 A1 940323 (Basic)  
EP 587780 B1 950215

WO 9221375 921210

APPLICATION (CC, No, Date): EP 92913710 920605; WO 92NL96

920605 PRIORITY (CC, No, Date): EP 91201398 910606; EP 92200781

920318 DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT;  
LI; LU; MC; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/12; G01N-033/569;  
C12N-007/00; LANGUAGE (Publication,Procedural,Application):

English; English; English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
----------------	----------	--------	------------

CLAIMS B	(English)	EPBBF2	781
----------	-----------	--------	-----

CLAIMS B	(German)	EPBBF2	699
----------	----------	--------	-----

CLAIMS B	(French)	EPBBF2	953
----------	----------	--------	-----

SPEC B	(English)	EPBBF2	10897
--------	-----------	--------	-------

Total word count - document A	0
-------------------------------	---

Total word count - document B	13330
-------------------------------	-------

Total word count - documents A + B	13330
------------------------------------	-------

6/3/17 (Item 13 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00563056

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Prostaglandin E receptors, their DNA and production.  
Prostaglandin-E-Rezeptoren, deren DNA und Herstellung.  
Recepteurs du Prostaglandine E, leur ADN et leur production.  
PATENT ASSIGNEE:

Takeda Chemical Industries, Ltd., (204702), 1-1 Doshomachi  
4-chome, Chuo-ku, Osaka-shi, Osaka 541, (JP), (applicant  
designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Ichikawa, Atsushi, 10-1-608, Besshohonmachi, Takatsuki, Osaka  
569, (JP) Narumiya, Shuh, 9-17, Goryo-oheyamacho 5-chome,  
Nishikyo-ku, Kyoto 610-11, (JP)

LEGAL REPRESENTATIVE:

Keller, Gunter, Dr. et al (59792), Lederer, Keller & Riederer,  
Patentanwalte, Lucile-Grahn-Strasse 22, D-81675 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 557966 A1 930901 (Basic)

APPLICATION (CC, No, Date): EP 93102873 930224;

PRIORITY (CC, No, Date): JP 9236580 920224; JP 9264889 920323

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT;  
LI; LU; NL; PT; SE

INTERNATIONAL PATENT CLASS: C07K-013/00; C12N-005/10;

C12N-015/12; C12N-015/70; C12N-015/75; C12N-015/81;

C12N-015/85;

ABSTRACT WORD COUNT: 84

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	418
SPEC A	(English)	EPABF1	6366
Total word count - document A			6784
Total word count - document B			0
Total word count - documents A + B			6784

6/3/18 (Item 14 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00547873

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Mutated form of the beta-amyloid precursor protein  
gene.

Mutierte Form von dem Beta-Amyloidprecursor Proteine Gen.  
Forme mutée du gene de la proteine du precurseur beta-amyloide.

PATENT ASSIGNEE:

N.V. INNOGENETICS S.A., (713141), Industriepark Zwijnaarde 7,  
Box 4, B-9710 Gent, (BE), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

Van Broeckhoven, Christine Neurogenetics Lab., Born-Bunge  
Found. Univ. of Antwerp(UIA) Dept.Chem., Universiteitsplein 1

B-2610 Antwerpen, (BE) Martin, Jean-Jacques Neuropathology  
Lab., Born-Bunge Found. Univ. of Antwerp (UIA),  
Universiteitsplein 1 B-2610 Antwerpen, (BE) Hendriks, Lydia  
Neurogen.Lab. Born-Bunge Found., Univ. of Antwerp(UIA) Dept.  
of Biochem., Universiteitsplein 1 B-2610 Antwerpen, (BE) Cras,  
Patrick Neurobiology Lab., Born-Bunge Found. Univ. of  
Antwerp(UIA), Universiteitsplein 1 B-2610 Antwerpen, (BE)

LEGAL REPRESENTATIVE:

Gutmann, Ernest et al (15992), Ernest Gutmann - Yves Plasseraud  
S.A. 3, rue Chauveau-Lagarde, F-75008 Paris, (FR)  
PATENT (CC, No, Kind, Date): EP 561087 A1 930922 (Basic)  
APPLICATION (CC, No, Date): EP 92400771 920320;  
PRIORITY (CC, No, Date): EP 92400771 920320  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
LU; MC; NL; PT; SE  
INTERNATIONAL PATENT CLASS: C07K-015/00; C12N-015/15;  
C12P-021/00; C12P-021/08; C12Q-001/68; G01N-033/53;  
C12N-015/00;  
ABSTRACT WORD COUNT: 84

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1519
SPEC A	(English)	EPABF1	5345
Total word count - document A			6864
Total word count - document B			0
Total word count - documents A + B			6864

6/3/19 (Item 15 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00538761

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Hybrid polypeptide containing an avidin binding  
polypeptide. Hybrides Polypeptide, das ein Avidin bindendes  
Polypeptide enthalt. Polypeptide hybride contenant une  
polypeptide de liaison avec avidin. PATENT ASSIGNEE:

ROHM AND HAAS COMPANY, (211420), Independence Mall West,  
Philadelphia Pennsylvania 19105, (US), (applicant designated  
states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;MC;NL;PT;SE)  
INVENTOR:

Cress, Dean Ervin, 104 Leslie Lane, Souderton, Pennsylvania  
18964, (US) Haase, Ferdinand Carl, 53 Skyline Drive, Chalfont,  
Pennsylvania 18914, (US)

LEGAL REPRESENTATIVE:

Harding, Charles Thomas et al (70741), Rohm and Haas (UK) Ltd.,  
European Operations Patent Dept., Lennig House, 2 Masons  
Avenue, Croydon CR9 3NB, (GB)

PATENT (CC, No, Kind, Date): EP 511747 A1 921104 (Basic)  
APPLICATION (CC, No, Date): EP 92303067 920407;  
PRIORITY (CC, No, Date): US 687819 910419



DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
LU; MC; NL; PT; SE  
INTERNATIONAL PATENT CLASS: C12N-015/62; C07K-003/18;  
C07K-013/00; C12N-005/00  
ABSTRACT WORD COUNT: 139

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	789
SPEC A	(English)	EPABF1	13682
Total word count - document A			14471
Total word count - document B			0
Total word count - documents A + B			14471

6/3/20 (Item 16 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00533453  
\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Recombinant vaccine against Marek's disease.  
Rekombinanter Impfstoff gegen Marek's Krankheit.  
Vaccin recombinant contre la maladie de Marek.

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, NL-6824 BM Arnhem,  
(NL), (applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

Morgan, Robin Wilson, 9 Middleton Lane, Landenberg,  
Pennsylvania 19350, (US)  
Claessens, Johannes Antonius Joseph, Van Speijk 52, NL-5831 LE  
Boxmeer, (NL)  
Sondermeijer, Paulus Jacobus Antonius, Mahonie 21, NL-5831 BN  
Boxmeer, (NL)

LEGAL REPRESENTATIVE:

Hermans, Franciscus G.M. et al (20114), P.O. Box 20, NL-5340 BH  
Oss, (NL)

PATENT (CC, No, Kind, Date): EP 513921 A2 921119 (Basic)  
EP 513921 A3 930616  
EP 513921 B1 950809

APPLICATION (CC, No, Date): EP 92201357 920513;

PRIORITY (CC, No, Date): US 699467 910514

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
LU; MC; NL; PT; SE

INTERNATIONAL PATENT CLASS: C12N-015/38; C07K-014/055;  
C07K-016/08; A61K-039/255;

ABSTRACT WORD COUNT: 68

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	371

CLAIMS B	(English)	EPAB95	848
CLAIMS B	(German)	EPAB95	798
CLAIMS B	(French)	EPAB95	963
SPEC A	(English)	EPABF1	8298
SPEC B	(English)	EPAB95	8298
Total word count	- document A		8670
Total word count	- document B		10907
Total word count	- documents A + B		19577

6/3/21 (Item 17 from file: 348)  
 DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00533042

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* Cloning and expression of genes encoding  
 arabinan-degrading enzymes of fungal origin.  
 Klonierung und Expression von Genen, kodierend für Enzyme aus  
 Pilzen, die Arabinan abbauen.  
 Clonage et expression de genes codant pour des enzymes  
 d'origine fongique dégradant l'arabinane.

PATENT ASSIGNEE:

GIST-BROCADES N.V., (200381), Wateringseweg 1 P.O. Box 1,  
 NL-2600 MA Delft, (NL), (applicant designated states:  
 AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

van Heuvel, Margaretha, Cobetstraat 19, NL-2313 KA Leiden,  
 (NL) Bakhuis, Janna Gardina, van der Haertstraat 72, NL-2613 ZC  
 Delft, (NL) Coutel, Yves, 56, Rue Culmette Guirin, F-59710  
 Ennevelin, (FR) Harder, Abraham, de Vaert 9, NL-2651 EP Berkel  
 en Rodenrijs, (NL) de Graaff, Leendert Hendrik, Cornelis  
 Koningstraat 8, NL-6862 CK Oosterbeek, (NL)  
 Flipphi, Michel Johannes Anthonie, Thorbeckestraat 234, NL-6702  
 BZ Wageningen, (NL)

van der Veen, Peter, A. Kuyperstraat 10, NL-6703 BL  
 Wageningen, (NL) Visser, Jacob, Hinkeloordseweg 5, NL-6703 CK  
 Wageningen, (NL) Andreoli, Peter Michael, Bellegemsestraat 57,  
 B-8510 Bellegem-Kortrijk, (BE)

LEGAL REPRESENTATIVE:

Visser-Luirink, Gesina, Dr. et al (69841), c/o GIST-BROCADES  
 N.V., Patents and Trademarks Dept., Wateringseweg 1, P.O. Box  
 1, NL-2600 MA Delft, (NL)

PATENT (CC, No, Kind, Date): EP 506190 A1 920930 (Basic)

APPLICATION (CC, No, Date): EP 92200818 920320;

PRIORITY (CC, No, Date): EP 91200720 910327

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
 LU; MC; NL; PT; SE

INTERNATIONAL PATENT CLASS: C12N-015/56; C12N-009/24;

ABSTRACT WORD COUNT: 61

LANGUAGE (Publication,Procedural,Application): English; English;

English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
----------------	----------	--------	------------

CLAIMS A	(English)	EPABF1	1501
SPEC A	(English)	EPABF1	18672
Total word count	- document A		20173
Total word count	- document B		0
Total word count	- documents A + B		20173

6/3/22 (Item 18 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00505517

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* DNA SEQUENCE FOR A SERINE PROTEASE AND ASSOCIATED  
 ITEMS.

DNA-SEQUENZ FUR EINE SERIN-PROTEASE UND DAMIT ZUSAMMENHANGENDE  
 GEGENSTANDE. SEQUENCE D'ADN POUR UNE PROTEASE DE SERINE ET OBJETS  
 S'Y RAPPORTANT. PATENT ASSIGNEE:

LUDEMANN, Jens, (1982850), Scharnhorststrasse 10, D-24105 Kiel,  
 (DE), (applicant designated states:  
 AT;BE;CH;DE;DK;FR;GB;IT;LI;NL;SE) UTECHT, Bert, (1982860),  
 Wildenhorster Weg 18, D-24211 Rastorf, (DE), (applicant  
 designated states: AT;BE;CH;DE;DK;FR;GB;IT;LI;NL;SE) INVENTOR:

JENNE, Dieter, E., Chemin des Boveresses 155, CH-1066  
 Epalinges, (CH) TSCHOPP, Jurg, Chemin des Boveresses 155,  
 CH-1066 Epalinges, (CH) LUDEMANN, Jens, Chemin des Boveresses  
 155, CH-1066 Epalinges, (CH) UTECHT, Bert, Chemin des  
 Boveresses 155, CH-1066 Epalinges, (CH) GROSS, Wolfgang, L.,  
 Chemin des Boveresses 155, CH-1066 Epalinges, (CH) LEGAL  
 REPRESENTATIVE:

Boeters, Hans Dietrich, Dr. et al (2193), Patentanwalte Boeters  
 & Bauer, Bereiteranger 15, D-81541 Munchen, (DE)  
 PATENT (CC, No, Kind, Date): EP 535059 A1 930407 (Basic)

EP 535059 B1 951129

WO 9200378 920109

APPLICATION (CC, No, Date): EP 91911228 910620; WO 91EP1142  
 910620 PRIORITY (CC, No, Date): DE 4019984 900622

DESIGNATED STATES: AT; BE; CH; DE; DK; FR; GB; IT; LI; NL; SE  
 INTERNATIONAL PATENT CLASS: C12N-015/57;

LANGUAGE (Publication,Procedural,Application): German; German;  
 German FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB95	285
CLAIMS B	(German)	EPAB95	251
CLAIMS B	(French)	EPAB95	309
SPEC B	(German)	EPAB95	3046
Total word count	- document A		0
Total word count	- document B		3891
Total word count	- documents A + B		3891

6/3/23 (Item 19 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00488958

\*\*ORDER fax of complete patent from KR SourceOne. See HELP

ORDER348\*\* Protease from Bacillus licheniformis

Protease aus Bacillus licheniformis

Protease de Bacillus licheniformis

PATENT ASSIGNEE:

SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of  
SHIONOGI & CO. LTD., (207413), 1-8, Doshomachi 3-chome,  
Chuo-ku, Osaka 541, (JP), (applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Teraoka, Hiroshi, 2-47-10, Takakuradai, Sakai-shi, Osaka, (JP)  
Tamaki, Mikio, 1-2446-6, Sakinaka-machi, Nara-shi, Nara-ken, (JP)  
Nakamura, Etsuo, 4573-41, Karato, Arino-cho, Kita-ku, Kobe-shi,  
Hyogo-ken, (JP)

Shin, Masaru, 3-110, Koryo-cho, Kita-ku, Kobe-shi, Hyogo-ken,  
(JP) Yoshida, Nobuo, 5-8, Koshiensanban-cho, Nishinomiya-shi,  
Hyogo-ken, (JP) Tsuzuki, Hiroshige, 5-12-15, Ohsumigaoka,  
Tanabe-cho, Tsuzuki-gun, Kyoto, (JP)

Fujiwara, Takashi, 3-7-2, Tezukayama, Nara-shi, Nara-ken, (JP)  
Matsumoto, Koichi, 1-929-1-401, Mukogaoka, Toyonaka-shi, Osaka,  
(JP) LEGAL REPRESENTATIVE:

Nash, David Allan et al (59252), Haseltine Lake & Co. Hazlitt  
House 28 Southampton Buildings Chancery Lane, London WC2A  
1AT, (GB) PATENT (CC, No, Kind, Date): EP 482879 A2 920429  
(Basic) EP 482879 A3 920520

EP 482879 B1 951227

APPLICATION (CC, No, Date): EP 91309737 911022;

PRIORITY (CC, No, Date): JP 90288110 901024

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;

LU; NL; SE INTERNATIONAL PATENT CLASS: C12N-015/57; C12N-009/56;  
C12N-001/21; C12N-009/56; C12R-001/10; C12N-001/21; C12R-001/07

ABSTRACT WORD COUNT: 51

LANGUAGE (Publication,Procedural,Application): English; English;

English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	345
SPEC A	(English)	EPABF1	7576
Total word count - document A			7921
Total word count - document B			0
Total word count - documents A + B			7921

6/3/24 (Item 20 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00478704

\*\*ORDER fax of complete patent from KR SourceOne. See HELP

ORDER348\*\* Marek's disease virus vaccine.

Virusimpfstoff gegen die Mareksche Krankheit.

Vaccin viral contre la maladie de Marek.

PATENT ASSIGNEE:

AKZO N.V., (200759), Velperweg 76, NL-6824 BM Arnhem, (NL),  
 (applicant designated states:  
 AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE) INVENTOR:  
 Morgan, Robin Wilson, 9 Middleton Lane, Landenberg,  
 Pennsylvania 19350, (US)  
 LEGAL REPRESENTATIVE:  
 Hermans, Franciscus G.M. et al (20114), P.O. Box 20, NL-5340 BH  
 Oss, (NL)  
 PATENT (CC, No, Kind, Date): EP 486106 A2 920520 (Basic)  
 EP 486106 A3 921223  
 APPLICATION (CC, No, Date): EP 91202947 911113;  
 PRIORITY (CC, No, Date): US 615211 901116  
 DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
 LU; NL; SE INTERNATIONAL PATENT CLASS: C12N-015/38; C12N-015/86;  
 C12N-005/10; A61K-039/255; A61K-039/395; C12P-021/00;  
 ABSTRACT WORD COUNT: 53

LANGUAGE (Publication,Procedural,Application): English; English;  
 English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	338
SPEC A	(English)	EPABF1	7764
Total word count - document A			8102
Total word count - document B			0
Total word count - documents A + B			8102

6/3/25 (Item 21 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00478543

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* Chicken anemia virus vaccine and diagnostic reagent.  
 Impfstoff und Diagnostikum fur Huhner-Anamie-Virus.  
 Vaccin et diagnostic concernant le virus de l'anemie des poulets.  
 PATENT ASSIGNEE:

AKZO N.V., (200759), Velperweg 76, NL-6824 BM Arnhem, (NL),  
 (applicant designated states:  
 BE;CH;DE;ES;FR;GB;GR;IT;LI;NL;SE)  
 INVENTOR:

Sondermeijer, Paulus Jacobus Antonius, Mahonie 21, NL-5831 RN  
 Boxmeer, (NL)

Claessens, Johannes Antonius Joseph, Mees 25, NL-5831 MR  
 Boxmeer, (NL) LEGAL REPRESENTATIVE:

Hermans, Franciscus G.M. et al (20114), P.O. Box 20, NL-5340 BH  
 Oss, (NL)

PATENT (CC, No, Kind, Date): EP 483911 A2 920506 (Basic)  
 EP 483911 A3 930224

APPLICATION (CC, No, Date): EP 91202737 911023;

PRIORITY (CC, No, Date): US 605881 901031

DESIGNATED STATES: BE; CH; DE; ES; FR; GB; GR; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/34; A61K-039/235;  
 A61K-039/395; C12N-007/00; C12P-021/02; G01N-033/569;



ABSTRACT WORD COUNT: 67

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	516
SPEC A	(English)	EPABF1	8348
Total word count - document A			8864
Total word count - document B			0
Total word count - documents A + B			8864

6/3/26 (Item 22 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00477472

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Chimeric plasminogen activators.

Chimare Plasminogenaktivatoren.

Activeurs de plasminogene chimeriques.

PATENT ASSIGNEE:

Leuven Research & Development V.Z.W., (229140), Benedenstraat  
59A Groot Begijnhof, B-3000 Leuven, (BE), (applicant  
designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Collen, Desire J., Schoonzichtlaan 2, B-Winksele, (BE)

Lijnen, Roger H., Acacialaan 50A, B-Herent, (BE)

Nelles, Lucien G.R., Dellestraat 20, B-Herent, (BE)

Stassen, Jean-Marie E.I., Jozef Ravoetstraat 5, B-Wilsele, (BE)

LEGAL REPRESENTATIVE:

Bruin, Cornelis Willem et al (19523), OCTROOIBUREAU ARNOLD &  
SIEDSMA Sweelinckplein 1, NL-2517 GK The Hague, (NL)

PATENT (CC, No, Kind, Date): EP 462651 A1 911227 (Basic)

APPLICATION (CC, No, Date): EP 91201447 910611;

PRIORITY (CC, No, Date): US 538458 900615

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;

LU; NL; SE INTERNATIONAL PATENT CLASS: C12N-015/58; C12N-009/72;

C12N-005/10; A61K-037/54;

ABSTRACT WORD COUNT: 108

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1033
SPEC A	(English)	EPABF1	10350
Total word count - document A			11383
Total word count - document B			0
Total word count - documents A + B			11383

6/3/27 (Item 23 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00453754

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* METHODS AND MATERIALS FOR EXPRESSION OF HUMAN  
PLASMINOGEN VARIANT. METHODEN UND MATERIALIEN ZUR EXPRESSION  
VON VARIANTEN VON MENSCHLICHEM PLASMINOGEN.  
PROCEDES ET MATIERES D'EXPRESSION DE VARIANTE DE PLASMINOGENE  
HUMAIN. PATENT ASSIGNEE:

GENENTECH, INC., (210483), 480 Point San Bruno Boulevard, San  
Francisco, CA 94080, (US), (applicant designated states:  
AT;BE;CH;DE;DK;FR;GB;LI;LU;NL;SE)

INVENTOR:

CASTELLINO, Francis, J., 16056 Baywood Lane, Granger, IN 46530,  
(US) HIGGINS, Deborah, L., 115 Crestview Court, San Carlos, CA  
94070, (US) LEGAL REPRESENTATIVE:

Nicholls, Kathryn Margaret et al (60341), MEWBURN ELLIS York  
House 23 Kingsway, London WC2B 6HP, (GB)  
PATENT (CC, No, Kind, Date): EP 502872 A1 920916 (Basic)

EP 502872 B1 940518

WO 9108297 910613

APPLICATION (CC, No, Date): EP 90916888 901031; WO 90US6345

901031 PRIORITY (CC, No, Date): US 444584 891201

DESIGNATED STATES: AT; BE; CH; DE; DK; FR; GB; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/57; C12N-009/68;

C12N-005/10; C12N-001/21; A61K-037/54;

LANGUAGE (Publication,Procedural,Application): English; English;

English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	884
CLAIMS B	(German)	EPBBF1	808
CLAIMS B	(French)	EPBBF1	1017
SPEC B	(English)	EPBBF1	16999
Total word count - document A			0
Total word count - document B			19708
Total word count - documents A + B			19708

6/3/28 (Item 24 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00429057

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Infectious bronchitis virus vaccine.  
Impfstoff gegen IBV.

Vaccin contre le virus de la bronchite infectieuse (IBV).

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, NL-6824 BM Arnhem,  
(NL), (applicant designated states:

BE;CH;DE;ES;FR;GB;GR;IT;LI;NL;SE) INVENTOR:

Sondermeijer, Paulus Jacobus Antonius, Mahonie 21, NL-5831 RN  
Boxmeer, (NL)

Claessens, Johannes Antonius Joseph, Mees 25, NL-5831 MR

Boxmeer, (NL) LEGAL REPRESENTATIVE:

Hermans, Franciscus G.M. et al (20111), Patent Department AKZO

NOBEL N.V. Pharma Division P.O. Box 20, NL-5340 BH Oss, (NL)  
PATENT (CC, No, Kind, Date): EP 423869 A1 910424 (Basic)  
EP 423869 B1 950712

APPLICATION (CC, No, Date): EP 90202667 901008;  
PRIORITY (CC, No, Date): US 424793 891020  
DESIGNATED STATES: BE; CH; DE; ES; FR; GB; GR; IT; LI; NL; SE  
INTERNATIONAL PATENT CLASS: C12N-015/50; C12N-015/86;  
C12N-015/62; C12P-021/00; A61K-039/215; C07K-014/00;  
ABSTRACT WORD COUNT: 75

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	348
CLAIMS B	(English)	EPAB95	626
CLAIMS B	(German)	EPAB95	544
CLAIMS B	(French)	EPAB95	676
SPEC A	(English)	EPABF1	6087
SPEC B	(English)	EPAB95	5829
Total word count - document A			6435
Total word count - document B			7675
Total word count - documents A + B			14110

6/3/29 (Item 25 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00422906

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Nucleic acid amplification employing transcribable  
hairpin probe. Nukleinsäure-Amplifikation unter Verwendung  
von transkriptionsfähiger Haarnadelsonde.  
Amplification d'acide nucleique employant une sonde  
transcriptible en forme d'épingle à cheveux.

PATENT ASSIGNEE:

MOLECULAR DIAGNOSTICS, INC., (594530), 400 Morgan Lane, West  
Haven, CT 06516, (US), (applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Dattagupta, Nanibhushan, 470 Prospect Street, New Haven, CT  
06511, (US) LEGAL REPRESENTATIVE:

Danner, Klaus, Dr. et al (51861), c/o Bayer AG  
Konzernverwaltung RP Patentabteilung, W-5090 Leverkusen 1  
Bayerwerk, (DE)

PATENT (CC, No, Kind, Date): EP 427074 A2 910515 (Basic)  
EP 427074 A3 910828

APPLICATION (CC, No, Date): EP 90120652 901027;  
PRIORITY (CC, No, Date): US 433947 891109; US 569992 900823  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
LU; NL; SE INTERNATIONAL PATENT CLASS: C12Q-001/68; C12N-015/10;  
ABSTRACT WORD COUNT: 173

LANGUAGE (Publication,Procedural,Application): English; English;

English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	598
SPEC A	(English)	EPABF1	8919
Total word count - document A			9517
Total word count - document B			0
Total word count - documents A + B			9517

6/3/30 (Item 26 from file: 348)  
 DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00409994

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* MONOCLONAL ANTIBODIES TO THE LIGHT CHAIN REGION OF  
 HUMAN FACTOR XII AND METHODS OF PREPARING AND USING THE SAME.  
 MONOKLONALE ANTIKORPER GEGEN DEN BEREICH DER LEICHTEN  
 KETTE VON MENSCHLICHEM FAKTOR XII SOWIE METHODEN ZU  
 DEREN HERSTELLUNG UND VERWENDUNG.  
 ANTICORPS MONOCLONAUX CONTRE LA REGION A CHAINE LEGERE DU  
 FACTEUR HUMAIN XII ET PROCEDES DE PREPARATION ET  
 D'UTILISATION DE CES ANTICORPS. PATENT ASSIGNEE:

Temple University of the Commonwealth System of Higher  
 Education, (512215), , Philadelphia PA 19122, (US),  
 (applicant designated states:  
 AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

PIXLEY, Robin, A., 5040 Copley Road, Philadelphia, PA 19144,  
 (US) COLMAN, Robert, W., 9 Rose Valley Road, Moylan, PA 19065,  
 (US) LEGAL REPRESENTATIVE:

W.P. THOMPSON & CO. (101053), Eastcheap House Central Approach,  
 Letchworth, Hertfordshire SG6 3DS, (GB)

PATENT (CC, No, Kind, Date): EP 419574 A1 910403 (Basic)  
 EP 419574 A1 910502

EP 419574 B1 951108  
 WO 8911865 891214

APPLICATION (CC, No, Date): EP 89907964 890526; WO 89US2211  
 890526 PRIORITY (CC, No, Date): US 204657 880609

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE  
 INTERNATIONAL PATENT CLASS: A61K-039/395; C07K-016/36;  
 C12N-015/00; C12N-005/02;

LANGUAGE (Publication,Procedural,Application): English; English;  
 English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB95	831
CLAIMS B	(German)	EPAB95	857
CLAIMS B	(French)	EPAB95	961
SPEC B	(English)	EPAB95	8217
Total word count - document A			0
Total word count - document B			10866
Total word count - documents A + B			10866

6/3/31 (Item 27 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00401785

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Polypeptides and polypeptide analogues with  
inhibitory activity against human elastase  
Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivitat  
gegenuber menschlicher Elastase  
Polypeptides et analogues de polypeptides ayant une activite  
inhibitrice vis-a-vis de l'elastase humaine

PATENT ASSIGNEE:

ZENECA LIMITED, (1579441), 15 Stanhope Gate, London W1Y 6LN,  
(GB), (applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Christophers, Enno, Prof., Schlossgarten 12, D-2300 Kiel 1,  
(DE) Schroder, Jens-Michael, Dr., Kleiner Bornkrug 7, D-2301  
Blumenthal, (DE) Pioli, David, Dr., 136 Rush Green Road, Lymn,  
Cheshire WA13 9QW, (GB) Wiedow, Oliver, Dr., Jahnstrasse 10,  
D-2300 Kiel 1, (DE) Edge, Michael Derek, Dr., 6 Tudor Way,  
Congleton, Cheshire, (GB) LEGAL REPRESENTATIVE:

Mack, John Richard et al (48504), Intellectual Property  
Department ZENECA Pharmaceuticals Mereside Alderley Park,  
Macclesfield, Cheshire SK10 4TG, (GB)

PATENT (CC, No, Kind, Date): EP 402068 A1 901212 (Basic)  
EP 402068 B1 951213

APPLICATION (CC, No, Date): EP 90306037 900604;

PRIORITY (CC, No, Date): GB 8913346 890609; GB 8913349 890609; GB  
8921613 890925; GB 8924717 891102

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
LU; NL; SE INTERNATIONAL PATENT CLASS: C07K-007/00; C12N-015/15;  
C12N-001/21; C12N-001/19; C12Q-001/68; A61K-038/55;  
C12P-021/08; A61K-039/395; ABSTRACT WORD COUNT: 54

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	637
SPEC A	(English)	EPABF1	13214
Total word count - document A			13851
Total word count - document B			0
Total word count - documents A + B			13851

6/3/32 (Item 28 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00399341

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* RNA ribozyme restriction endoribonucleases and  
methods.



RNA-Ribozym-Restriktionsendonukleasen und Methoden.  
ARN ribozymes comme endoribonucleases de restriction et methodes.  
PATENT ASSIGNEE:

UNIVERSITY PATENTS, INC., (226643), 1465 Post Road East,  
Westport Connecticut 06881, (US), (applicant designated  
states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Cech, Thomas R., 1545 Rockmont Cir., Boulder, Colorado 80303,  
(US) Murphy, Felicia L., 705 Aurora, Apt. 4, Boulder, Colorado  
80302, (US) Zaug, Arthur J., 623 W. Lilac Ct., Louisville,  
Colorado 80027, (US) Grosshans, Cheryl, 11 West Ellsworth  
Avenue, Apt. 17, Denver, Colorado 80223, (US)

LEGAL REPRESENTATIVE:

Allam, Peter Clerk et al (27601), LLOYD WISE, TREGEAR & CO.  
Norman House 105-109 Strand, London WC2R 0AE, (GB)  
PATENT (CC, No, Kind, Date): EP 389299 A1 900926 (Basic)  
APPLICATION (CC, No, Date): EP 90303146 900323;  
PRIORITY (CC, No, Date): US 328503 890324  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
LU; NL; SE INTERNATIONAL PATENT CLASS: C12N-009/22; C12N-009/00;  
C12P-019/34; ABSTRACT WORD COUNT: 31

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	433
SPEC A	(English)	EPABF1	21114
Total word count - document A			21547
Total word count - document B			0
Total word count - documents A + B			21547

6/3/33 (Item 29 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00396377

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Vampire bat salivary Plasminogen activator vPA-alpha 1  
Fledermausspeichel-Plasminogenaktivator vPA-alpha 1  
Activateur du plasminogene salivaires de chauve-souris vPA-alpha  
1 PATENT ASSIGNEE:

SCHERING AKTIENGESSELLSCHAFT, (201588), Mullerstrasse 170/178,  
D-13353 Berlin, (DE), (applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Baldus, Berthold, Joachim-Friedrich-Strasse 13, D-1000 Berlin  
31, (DE) Donner, Peter, Steglitzer Damm 7a, D-1000 Berlin 41,  
(DE) Schleuning, Wolf-Dieter, Am Pichelsee 36a, D-1000 Berlin  
20, (DE) Alagon, Alejandro, Cuernavaca, Mor. 62271, (MX)  
Boidol, Werner, Nassauische Strasse 16a, D-1000 Berlin 31, (DE)  
Kratzschmar, Jorn Reiner, Further Strasse 5, D-1000 Berlin 30,  
(DE) Haendler, Bernhard Jacques, Friedbergstrasse 34, D-1000  
Berlin 19, (DE) Langer, Gernot, Wilhelmhavener Strasse 63,

D-1000 Berlin 21, (DE) PATENT (CC, No, Kind, Date): EP 383417  
A1 900822 (Basic) EP 383417 B1  
951227

APPLICATION (CC, No, Date): EP 90250043 900213;  
PRIORITY (CC, No, Date): DE 3904580 890213; DE 3917949 890530  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;  
LU; NL; SE INTERNATIONAL PATENT CLASS: C12N-009/64; C12N-015/58;  
C12N-001/21; A61K-038/48;  
ABSTRACT WORD COUNT: 32

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	718
SPEC A	(English)	EPABF1	8006
Total word count - document A			8724
Total word count - document B			0
Total word count - documents A + B			8724

6/3/34 (Item 30 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00395465

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Hog cholera virus vaccine and diagnostic.  
Impfstoff und Diagnostikum fur den Schweine-Cholera-Virus. Vaccin  
et test de diagnostic pour le virus du cholera porcin. PATENT  
ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, NL-6824 BM Arnhem,  
(NL), (applicant designated states:  
BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;NL;SE) INVENTOR:

Meyers, Gregor, Gammertingerstrasse 79, D-7000 Stuttgart 80,  
(DE) Rumenapf, Tillmann, Ligusterweg 3, D-7400 Tubingen, (DE)  
Thiel, Heinz-Jurgen, Im Schonblick 67, D-7400 Tubingen, (DE)  
LEGAL REPRESENTATIVE:

Hermans, Franciscus G.M. et al (20111), Patent Department AKZO  
NOBEL N.V. Pharma Division P.O. Box 20, NL-5340 BH Oss, (NL)  
PATENT (CC, No, Kind, Date): EP 389034 A1 900926 (Basic)

EP 389034 B1 940914  
APPLICATION (CC, No, Date): EP 90200573 900312;  
PRIORITY (CC, No, Date): EP 89104921 890319  
DESIGNATED STATES: BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; NL; SE  
INTERNATIONAL PATENT CLASS: C12N-015/40; A61K-039/187;  
C12Q-001/70 ABSTRACT WORD COUNT: 61

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPBBF1	311
CLAIMS B	(English)	EPBBF1	667
CLAIMS B	(German)	EPBBF1	579
CLAIMS B	(French)	EPBBF1	767

SPEC A	(English)	EPBBF1	5759
SPEC B	(English)	EPBBF1	5726
Total word count - document A			6070
Total word count - document B			7739
Total word count - documents A + B			13809

6/3/35 (Item 31 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00385771

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* Method of detecting small cell carcinoma and use of  
 acylpeptide hydrolase encoding sequences therefor.  
 Verfahren zum Nachweis von kleinzelligem Carzinom und die  
 Verwendung von Sequenzen, die Acylpeptid-Hydrolase codieren,  
 fur diesen zweck. Procédé pour détecter des carcinomes du  
 type a petites cellules et utilisation a cet effet de  
 sequences d'acide nucleique codant pour l'hydrolase de  
 peptides ac

PATENT ASSIGNEE:

THE GENERAL HOSPITAL CORPORATION, (370400), 55 Fruit Street,  
 Boston, MA 02114, (US), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Smith, John A., 19 Thatcher Street, No. 5, Brookline, MA 02146,  
 (US) LEGAL REPRESENTATIVE:

Fischer, Hans-Jurgen, Dr. et al (70771), Hoechst AG Patent- und  
 Lizenzabteilung Gebaude K 801, D-65926 Frankfurt am Main, (DE)  
 PATENT (CC, No, Kind, Date): EP 378224 A2 900718 (Basic)

EP 378224 A3 911127

EP 378224 B1 950823

APPLICATION (CC, No, Date): EP 90100575 900112;

PRIORITY (CC, No, Date): US 296996 890113; US 429935 891101

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;

LU; NL; SE INTERNATIONAL PATENT CLASS: C12Q-001/68; C12N-015/57

ABSTRACT WORD COUNT: 18

LANGUAGE (Publication,Procedural,Application): English; English;  
 English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	413
SPEC A	(English)	EPABF1	11840
Total word count - document A			12253
Total word count - document B			0
Total word count - documents A + B			12253

6/3/36 (Item 32 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00381638

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* ELASTASE INHIBITING POLYPEPTIDES AND PROCESS FOR  
 THEIR PREPARATION BY GENETIC RECOMBINATION.  
 ELASTASE-INHIBIERUNGSPOLYPEPTIDE UND VERFAHREN ZUR  
 HERSTELLUNG DURCH GENETISCHE REKOMBINATION.  
 POLYPEPTIDES INHIBITEURS D'ELASTASE ET PROCEDE DE  
 PRODUCTION DE CES POLYPEPTIDES PAR RECOMBINAISON GENETIQUE.  
 PATENT ASSIGNEE:

TEIJIN LIMITED, (394080), 11 Minamihonmachi 1-chome Higashi-ku,  
 Osaka-shi Osaka 541, (JP), (applicant designated states:  
 AT;BE;CH;DE;FR;GB;IT;LI;NL;SE)

INVENTOR:

SUGIYAMA, Takashi, 3-18-4, Tamadaira, Hino-shi Tokyo 191, (JP)  
 KAMIMURA, Takashi, 2-7-12, Shinmei, Hino-shi Tokyo 191, (JP)  
 MASUDA, Kenichi, 2-23-8, Myojin-cho, Hachioji-shi Tokyo 192, (JP)  
 OKADA, Masahiro, Teijin Musashino Ryo 3-5-18, Tamadaira,  
 Hino-shi Tokyo 191, (JP)

OHTSUKA, Eiko, 18-1-3-614, Nishi Minamijyujyo, Chuo-ku,  
 Sapporo-shi Hokkaido 064, (JP)

LEGAL REPRESENTATIVE:

Dean, John Paul et al (72771), Withers & Rogers 4 Dyer's  
 Buildings Holborn, London EC1N 2JT, (GB)

PATENT (CC, No, Kind, Date): EP 346500 A1 891220 (Basic)  
 EP 346500 A1 910522

EP 346500 B1 940727

WO 8906239 890713

APPLICATION (CC, No, Date): EP 89900924 881228; WO 88JP1342

881228 PRIORITY (CC, No, Date): JP 87330219 871228

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: C07K-003/08; C07K-013/00;

C07K-015/12; C12P-021/02; C12N-015/00; C12N-009/99;

A61K-037/02; C12P-021/02; C12R-001/19

LANGUAGE (Publication,Procedural,Application): English; English;  
 Japanese FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	709
CLAIMS B	(German)	EPBBF1	662
CLAIMS B	(French)	EPBBF1	775
SPEC B	(English)	EPBBF1	8767
Total word count - document A			0
Total word count - document B			10913
Total word count - documents A + B			10913

6/3/37 (Item 33 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00373771

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* Labeling by simultaneous ligation and restriction.  
 Markierung durch gleichzeitige Ligation und Restriktion.  
 Marquage par ligation et restriction simultanee.  
 PATENT ASSIGNEE:

APPLIED BIOSYSTEMS, INC., (671590), 850 Lincoln Centre Drive,  
Foster City California 94404, (US), (applicant designated  
states:

CH;DE;FR;GB;IT;LI;SE)

INVENTOR:

Keith, Douglas H., 1145 Glencourt Drive, Oakland, CA 94611,  
(US) Kronick, Mel N., 1156 Forest Avenue, Palo Alto, CA 94301,  
(US) McBride, Lincoln J., 311 Iris Street, Redwood City, CA  
94062, (US) Whiteley, Norman M., 151 Highland Avenue, San  
Carlos, CA 94070, (US) LEGAL REPRESENTATIVE:

Warcoin, Jacques et al (19071), Cabinet Regimbeau 26, avenue  
Kleber, F-75116 Paris, (FR)

PATENT (CC, No, Kind, Date): EP 327429 A2 890809 (Basic)

EP 327429 A3 890816

EP 327429 B1 930922

APPLICATION (CC, No, Date): EP 89400220 890126;

PRIORITY (CC, No, Date): US 148757 880126

DESIGNATED STATES: CH; DE; FR; GB; IT; LI; SE

INTERNATIONAL PATENT CLASS: C12Q-001/68; C12N-015/10;

ABSTRACT WORD COUNT: 50

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	504
CLAIMS B	(German)	EPBBF1	512
CLAIMS B	(French)	EPBBF1	567
SPEC B	(English)	EPBBF1	3753
Total word count - document A			0
Total word count - document B			5336
Total word count - documents A + B			5336

6/3/38 (Item 34 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00372874

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Novel thrombolytic proteins, process for  
producing the same, and drugs containing the same as active  
ingredient.

Thrombolytische Proteine, Verfahren zu ihrer Herstellung und  
Medikamente, die sie als aktiven Bestandteil enthalten.  
Proteines thrombolytiques, procede pour les produire et  
medicaments les contenant comme substance active.

PATENT ASSIGNEE:

YAMANOUCHI PHARMACEUTICAL CO. LTD., (274782), No. 3-11  
Nihonbashi-Honcho, 2-chome Chuo-ku, Tokyo, (JP), (applicant  
designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Shimizu, Yasuaki, 10-15, Takashimadaira 2-chome Itabashi-ku,  
Tokyo 175, (JP)

Yano, Emiko, 33-8, Takashimadaira 8-chome Itabashi-ku, Tokyo



175, (JP) Yano, Shinya, 33-8, Takashimadaira 8-chome  
Itabashi-ku, Tokyo 175, (JP) Kato, Masao, 257-2, Asukai-cho  
Higashi-iru Horikawa Imadekawa, Kamikyo-ku Kyoto-shi Kyoto  
602, (JP)

Kinoshita, Akihito, 1-148, Hizen-cho, Takahagi-shi Ibaraki 318,  
(JP) Kawasaki, Tomihisa, 18-5, Sengen 1-chome, Tsukuba-shi  
Ibaraki 305, (JP) Ishida, Junko, 487-119, Hanakoganei 5-chome,  
Kodaira-shi Tokyo 187, (JP) Gushima, Hiroshi, 22-8, Asamada  
3-chome, Ageo-shi Saitama 362, (JP) LEGAL REPRESENTATIVE:

Geering, Keith Edwin et al (30911), REDDIE & GROSE 16 Theobalds  
Road, London WC1X 8PL, (GB)

PATENT (CC, No, Kind, Date): EP 373896 A1 900620 (Basic)

APPLICATION (CC, No, Date): EP 89312993 891212;

PRIORITY (CC, No, Date): JP 88314172 881212

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-009/64; C12N-015/58;

A61K-037/547; ABSTRACT WORD COUNT: 140

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	217
SPEC A	(English)	EPABF1	8045
Total word count - document A			8262
Total word count - document B			0
Total word count - documents A + B			8262

6/3/39 (Item 35 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00367834

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Overexpression of phytochrome in transgenic plants.  
Uberexpression von Phytochrom in transgenen Pflanzen.  
Expression pousse du phytochrome dans des plantes transgeniques.  
PATENT ASSIGNEE:

E.I. DU PONT DE NEMOURS AND COMPANY, (200580), 1007 Market  
Street, Wilmington Delaware 19898, (US), (applicant  
designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)  
INVENTOR:

Hershey, Howard P., 1129 Cockburn Drive, West Chester  
Pennsylvania 19382, (US)

Keller, Janis M., 21423 Tanglewood Drive, Castro Valley  
California 94546, (US)

LEGAL REPRESENTATIVE:

Hildyard, Edward Martin et al (31824), Frank B. Dehn & Co.  
European Patent Attorneys Imperial House 15-19 Kingsway,  
London WC2B 6UZ, (GB) PATENT (CC, No, Kind, Date): EP 354687 A1  
900214 (Basic) EP 354687 B1  
940928

APPLICATION (CC, No, Date): EP 89307658 890727;

PRIORITY (CC, No, Date): US 226344 880729; US 284422 881214

DESIGNATED STATES (Pub A): ES; GR; (Pub B): AT; BE; CH; DE; ES;  
FR; GB; GR; IT; LI; LU; NL; SE  
INTERNATIONAL PATENT CLASS: A01H-005/00; A01H-005/10;  
C12N-015/29; C12N-015/82;  
ABSTRACT WORD COUNT: 74

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPBBF1	552
CLAIMS B	(English)	EPBBF1	531
CLAIMS B	(German)	EPBBF1	524
CLAIMS B	(French)	EPBBF1	622
SPEC A	(English)	EPBBF1	17101
SPEC B	(English)	EPBBF1	16942
Total word count - document A			17653
Total word count - document B			18619
Total word count - documents A + B			36272

6/3/40 (Item 36 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00367393

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* A tissue plasminogen activator analogue.  
Gewebeplasminogenaktivator-Analog.  
Analogue de l'activateur tissulaire du plasminogene.  
PATENT ASSIGNEE:

NOVO-NORDISK A/S, (231781), Novo Alle, DK-2880 Bagsvaerd, (DK),  
(applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE) INVENTOR:  
Petersen, Lars Christian, Havevej 4,, DK-2970 Hoersholm, (DK)  
Boel, Esper, Lyngbakkevej 25, DK-2840 Holte, (DK)  
LEGAL REPRESENTATIVE:

Brown, John David et al (28811), FORRESTER & BOEHMERT  
Widenmayerstrasse 4/I, D-8000 Munchen 22, (DE)  
PATENT (CC, No, Kind, Date): EP 351246 A2 900117 (Basic)  
EP 351246 A3 900912

APPLICATION (CC, No, Date): EP 89307194 890714;  
PRIORITY (CC, No, Date): DK 883952 880715  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: C12N-009/64; C12N-015/58;  
C12N-005/10; A61K-037/547;  
ABSTRACT WORD COUNT: 82

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	724
SPEC A	(English)	EPABF1	5899
Total word count - document A			6623
Total word count - document B			0

Total word count - documents A + B 6623

6/3/41 (Item 37 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00366583

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Bovine factor Xa inhibiting factor and  
pharmaceutical compositions containing the same.  
Rinderfaktor-Xa-hemmender Faktor und diesen enthaltende  
pharmazeutische Zusammensetzungen.  
Facteur inhibant le facteur Xa bovin et compositions  
pharmaceutiques le contenant.  
PATENT ASSIGNEE:

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF  
JERUSALEM, (266883), 46 Jabotinsky Street, Jerusalem, 92  
182, (IL), (applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE) AMERICAN NATIONAL RED  
CROSS, (346810), 400 17th Street, N.W., Washington, DC 20006,  
(US), (applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Rigbi, Meir, 18, Habaron Hirsch Street, Jerusalem, (IL)  
Jackson, Craig, 22, Olbrook Lane, Grosse Pointe Farms,  
MI-48236/0010, (US)

LEGAL REPRESENTATIVE:

Hallybone, Huw George et al (53031), CARPMAELS AND RANSFORD 43  
Bloomsbury Square, London WC1A 2RA, (GB)  
PATENT (CC, No, Kind, Date): EP 352903 A2 900131 (Basic)  
EP 352903 A3 900613

EP 352903 B1 940302

APPLICATION (CC, No, Date): EP 89306345 890623;

PRIORITY (CC, No, Date): IL 86856 880624

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: A61K-035/02;

ABSTRACT WORD COUNT: 27

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	306
CLAIMS B	(German)	EPBBF1	301
CLAIMS B	(French)	EPBBF1	360
SPEC B	(English)	EPBBF1	1459
Total word count - document A			0
Total word count - document B			2426
Total word count - documents A + B			2426

6/3/42 (Item 38 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00366311

\*\*ORDER fax of complete patent from KR SourceOne. See HELP

ORDER348\*\* Novel glutathione peroxidase gene.

Glutathionperoxidase-Gen.

Gene codant pour la glutathione peroxidase.

PATENT ASSIGNEE:

TOYO JOZO KABUSHIKI KAISHA, (677940), 632-1 Mifuku Ohito-cho,  
Tagata-gun Shizuoka-ken, (JP), (applicant designated states:  
BE;CH;DE;ES;FR;GB;IT;LI;NL;SE)

INVENTOR:

Akasaka, Masami, 632-1 Mifuku Ohito-cho, Tagata-gun Shizuoka,  
(JP) Kubota, Akiko, 9-2 Tokiwa-cho SENbon, Numazu-shi Shizuoka,  
(JP) Mizoguchi, Junzo, 357-1 Onarimon Ohito-cho, Tagata-gun  
Shizuoka, (JP) Satoh, Sakae, 1012-17 Kashiya Kannami-cho,  
Tagata-gun Shizuoka, (JP) LEGAL REPRESENTATIVE:

Woods, Geoffrey Corlett et al (48721), J.A. KEMP & CO. 14 South  
Square Gray's Inn, London WC1R 5EU, (GB)

PATENT (CC, No, Kind, Date): EP 347224 A2 891220 (Basic)

EP 347224 A3 901205

APPLICATION (CC, No, Date): EP 89306071 890615;

PRIORITY (CC, No, Date): JP 88147884 880615

DESIGNATED STATES: BE; CH; DE; ES; FR; GB; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/00; C12N-001/20;

C12N-005/00; C12N-009/08;

ABSTRACT WORD COUNT: 49

LANGUAGE (Publication,Procedural,Application): English; English;

English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	200
SPEC A	(English)	EPABF1	6311
Total word count - document A			6511
Total word count - document B			0
Total word count - documents A + B			6511

6/3/43 (Item 39 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00361651

\*\*ORDER fax of complete patent from KR SourceOne. See HELP

ORDER348\*\* T cell activation markers.

Markierer der T-Zelle Aktivierung.

Marqueurs de l'activation des cellules T.

PATENT ASSIGNEE:

Schering Biotech Corporation, (636051), 901 California Avenue,  
Palo Alto California 94304-1104, (US), (applicant designated  
states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Brown, Keith D., 17 Woolwich Road, Hunters Hill New South Wales  
2110, (AU)

Mosmann, Timothy R., 69 Lloyd Drive, Atherton California  
94025, (US) Zurawski, Gerald, 1028 Wilmington Way, Redwood City

California 94062, (US)  
Zurawski, Sandra M., 1028 Wilmington Way, Redwood City  
California 94062, (US)

LEGAL REPRESENTATIVE:

Ritter, Stephen David et al (35281), Mathys & Squire 10 Fleet  
Street, London EC4Y 1AY, (GB)

PATENT (CC, No, Kind, Date): EP 329363 A1 890823 (Basic)  
EP 329363 B1 930331

APPLICATION (CC, No, Date): EP 89301341 890213;

PRIORITY (CC, No, Date): US 157743 880218

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-015/12; G01N-033/53;

C12P-021/02; ABSTRACT WORD COUNT: 59

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
----------------	----------	--------	------------

CLAIMS B	(English)	EPABF1	151
----------	-----------	--------	-----

SPEC B	(English)	EPABF1	5743
--------	-----------	--------	------

Total word count - document A	0
-------------------------------	---

Total word count - document B	5894
-------------------------------	------

Total word count - documents A + B	5894
------------------------------------	------

6/3/44 (Item 40 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00350372

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Isolation, purification, and characterization of the  
aminopeptidases: AP1 and AP122.

Isolierung, Reinigung und Charakterisierung von  
Aminopeptidasen AP2, AP1 und APX.

Isolation, purification et caracterisation des  
aminopeptidases AP1 et AP122.

PATENT ASSIGNEE:

THE GENERAL HOSPITAL CORPORATION, (370400), 55 Fruit Street,  
Boston MA 02114, (US), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Smith, John A., 19 Thatcher Street, No.5, Brookline  
Massachusetts 02146, (US)

Chang, Yie-Hwa, 91 Winslow Avenue, Somerville Massachusetts  
02143, (US) LEGAL REPRESENTATIVE:

Klein, Otto, Dr. et al (58251), Hoechst AG Zentrale  
Patentabteilung Postfach 80 03 20, D-6230 Frankfurt am Main  
80, (DE)

PATENT (CC, No, Kind, Date): EP 375841 A1 900704 (Basic)

APPLICATION (CC, No, Date): EP 89116735 890909;

PRIORITY (CC, No, Date): US 243734 880913

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-009/60; C12N-015/57;

ABSTRACT WORD COUNT: 39



LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1400
SPEC A	(English)	EPABF1	8535
Total word count - document A			9935
Total word count - document B			0
Total word count - documents A + B			9935

6/3/45 (Item 41 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00350371

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Isolation, purification, and characterization of the  
aminopeptidases: AP2, API, and APX.

Isolierung, Reinigung und Charakterisierung von  
Aminopeptidasen AP2, AP1 und APX.

Isolation, purification et caracterisation des amino peptidases  
AP2, AP1 et APX.

PATENT ASSIGNEE:

THE GENERAL HOSPITAL CORPORATION, (370400), 55 Fruit Street,  
Boston MA 02114, (US), (applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Smith, John A., 19 Thatcher Street No. 5, Brookline  
Massachusetts 02146, (US)

Chang, Yie-Hwa, 91 Winslow Avenue, Somerville Massachusetts  
02143, (US) LEGAL REPRESENTATIVE:

Klein, Otto, Dr. et al (58251), Hoechst AG Zentrale  
Patentabteilung Postfach 80 03 20, D-6230 Frankfurt am Main  
80, (DE)

PATENT (CC, No, Kind, Date): EP 359164 A2 900321 (Basic)  
EP 359164 A3 901114

APPLICATION (CC, No, Date): EP 89116734 890909;

PRIORITY (CC, No, Date): US 243733 880913; US 284244 881214

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-009/60; C12P-021/06;

ABSTRACT WORD COUNT: 49

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	2237
SPEC A	(English)	EPABF1	15129
Total word count - document A			17366
Total word count - document B			0
Total word count - documents A + B			17366

6/3/46 (Item 42 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00350370

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Isolation, purification, and characterization of the  
aminopeptidases: mas II and III.

Isolierung, Reinigung und Charakterisierung der Amino peptidasen

mas II und mas III.

Isolation, purification et caracterisation des amino peptidasen

mas II et mas III.

PATENT ASSIGNEE:

THE GENERAL HOSPITAL CORPORATION, (370400), 55 Fruit Street,  
Boston MA 02114, (US), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Smith, John A., 19 Thatcher Street No. 5, Brookline  
Massachusetts 02146, (US)

Chang, Yie-Hwa, 91 Winslow Avenue, Somerville Massachusetts  
02143, (US) LEGAL REPRESENTATIVE:

Klein, Otto, Dr. et al (58251), Hoechst AG Zentrale  
Patentabteilung Postfach 80 03 20, D-6230 Frankfurt am Main  
80, (DE)

PATENT (CC, No, Kind, Date): EP 359163 A2 900321 (Basic)  
EP 359163 A3 900502

APPLICATION (CC, No, Date): EP 89116733 890909;

PRIORITY (CC, No, Date): US 243737 880913

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-009/48; C12N-015/57;

C12P-021/06; ABSTRACT WORD COUNT: 39

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1254
SPEC A	(English)	EPABF1	7658
Total word count - document A			8912
Total word count - document B			0
Total word count - documents A + B			8912

6/3/47 (Item 43 from file: 348)

DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00344261

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* cDNAs coding for members of the carcinoembryonic

antigen family. cDNAs, die fur Mitglieder der

Karzinoembryonalantigen-Familie kodieren. ADNc codant pour

des membres de la famille d'antigenes

carcinoembryonnaires.

PATENT ASSIGNEE:

MILES INC., (923417), One Mellon Center 500 Grant Str.,  
Pittsburgh, PA 15219-2502, (US), (applicant designated

states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;NL;SE)

INVENTOR:

Barnett, Thomas R., Dr., 27 Jeffrey Road, East Haven, CT 06513,  
(US) Elting, James J., Dr., 5 Heatherwood Drive, Madison, CT  
06443, (US) Kamarck, Michael E., 86 Russell Road, Bethany, CT  
06525, (US) Kretschmer, Axel, Dr., Richard-Zorner-Strasse 32,  
D-5060 Bergisch Gladbach 1, (DE)

LEGAL REPRESENTATIVE:

Danner, Klaus, Dr. et al (51861), Bayer AG Konzernverwaltung RP  
Patente Konzern, D-51368 Leverkusen, (DE)

PATENT (CC, No, Kind, Date): EP 346710 A2 891220 (Basic)

EP 346710 A3 910911

EP 346710 B1 931110

APPLICATION (CC, No, Date): EP 89110096 890603;

PRIORITY (CC, No, Date): US 207678 880616; US 274107 881121

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/12; C12N-005/10;

C12P-021/02; ABSTRACT WORD COUNT: 107

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	212
CLAIMS B	(German)	EPBBF1	211
CLAIMS B	(French)	EPBBF1	252
SPEC B	(English)	EPBBF1	8470
Total word count - document A			0
Total word count - document B			9145
Total word count - documents A + B			9145

6/3/48 (Item 44 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00341128

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Method for determining state of disease progression.  
Verfahren zur Bestimmung des Krankheitsverlaufszustands.  
Procede pour la determination de l'etat de progression d'une  
maladie. PATENT ASSIGNEE:

MONTEFIORE MEDICAL CENTER, (1093220), 111 East 210th Street,  
New York New York, (US), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Augenlicht, Leonard H., 191 Redding Road, Redding Connecticut,  
(US) LEGAL REPRESENTATIVE:

Schmidt-Evers, Jorgen, Dipl.-Ing. (10431), , , ( )

PATENT (CC, No, Kind, Date): EP 337498 A2 891018 (Basic)

EP 337498 A3 910320

APPLICATION (CC, No, Date): EP 89106875 890417;

PRIORITY (CC, No, Date): US 182185 880415

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12Q-001/68; G01N-033/574;  
A61K-037/02; A61K-031/70; A61K-039/395;  
ABSTRACT WORD COUNT: 162

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	793
SPEC A	(English)	EPABF1	8048
Total word count - document A			8841
Total word count - document B			0
Total word count - documents A + B			8841

6/3/49 (Item 45 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00334450

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* HUMAN GAMMA, DELTA T CELL ANTIGEN RECEPTOR  
POLYPEPTIDES AND NUCLEIC ACIDS. MENSCHLICHE GAMMA,  
DELTA-T-ZELLEN-ANTIGEN-REZEPTOR-POLYPEPTIDE UND  
NUKLEINSAUREN.

POLYPEPTIDES RECEPTEURS D'ANTIGENES DE CELLULES T GAMMA, DELTA  
HUMAINE ET ACIDES NUCLEIQUES.

PATENT ASSIGNEE:

T CELL SCIENCES, INC., (875281), 38 Sidney Street, Cambridge,  
MA 02139-4135, (US), (applicant designated states:  
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

DANA-FARBER CANCER INSTITUTE, (550502), 44 Binney Street,  
Boston, MA 02115, (US), (applicant designated states:  
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE, (227952), 17  
Quincy Street, Cambridge, MA 02138, (US), (applicant  
designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

BRENNER, Michael, B., 99 Oak Street 73, Ashland, MA 01721,  
(US) IP, Stephen, H., 11 Singing Hill Circle, Sudbury, MA  
01776, (US) SEIDMAN, Jonathan, 1350 Canton Avenue, Milton, MA  
02186, (US) BAND, Hamid, 400 Brookline Avenue 5-C, Boston, MA  
02215, (US) LEGAL REPRESENTATIVE:

Silveston, Judith et al (35881), ABEL & IMRAY Northumberland  
House 303-306 High Holborn, London, WC1V 7LH, (GB)

PATENT (CC, No, Kind, Date): EP 345318 A1 891213 (Basic)  
EP 345318 A1 900905

EP 345318 B1 950503

WO 8903996 890505

APPLICATION (CC, No, Date): EP 88910391 881028; WO 88US3869

881028 PRIORITY (CC, No, Date): US 115256 871029; US 187698

880429 DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL;

SE INTERNATIONAL PATENT CLASS: G01N-033/53; C12N-015/00;

G01N-033/577; C07K-016/00; C07H-017/00;

ABSTRACT WORD COUNT: 218

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	878
CLAIMS B	(English)	EPAB95	1685
CLAIMS B	(German)	EPAB95	1531
CLAIMS B	(French)	EPAB95	1891
SPEC A	(English)	EPABF1	17229
SPEC B	(English)	EPAB95	17818
Total word count - document A			18109
Total word count - document B			22925
Total word count - documents A + B			41034

6/3/50 (Item 46 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00331058

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* METHOD AND COMPOSITIONS FOR MAKING ACSF AND ACSF  
ANTAGONISTS. METHODE UND VERBINDUNGEN ZUR HERSTELLUNG VON ACSF  
UND ACSF-ANTAGONISTEN. PROCEDE ET COMPOSITIONS PERMETTANT DE  
PRODUIRE LE FACTEUR DE STIMULATION D'ADENYLATE CYCLASE ET SES  
ANTAGONISTES.

PATENT ASSIGNEE:

GENENTECH, INC., (210484), Legal Department 460 Point San Bruno  
Boulevard, South San Francisco, CA 94080, (US), (applicant  
designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

THE UNIVERSITY OF MELBOURNE, (202591), Office of the Vice  
Principal, Parkville, Melbourne, Victoria 3052, (AU),  
(applicant designated states:  
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

MARTIN, Thomas, John, 6 Stoke Avenue, Victoria, VIC, (AU)  
SUVA, Larry, John, 16 Campbell Street, East Kew, VIC, (AU)  
WOOD, William, I., 1400 Tarrytown, San Mateo, CA 94402, (US)

LEGAL REPRESENTATIVE:

Stuart, Ian Alexander et al (50492), MEWBURN ELLIS 2 Cursitor  
Street, London EC4A 1BQ, (GB)

PATENT (CC, No, Kind, Date): EP 362272 A1 900411 (Basic)  
EP 362272 B1 931118

WO 8809376 881201

APPLICATION (CC, No, Date): EP 88905121 880519; WO 88US1652  
880519 PRIORITY (CC, No, Date): US 52637 870520

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/16; C12N-005/00;  
A61K-037/24; A61K-039/395; C12P-021/02; G01N-033/78;

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	828
CLAIMS B	(German)	EPBBF1	781
CLAIMS B	(French)	EPBBF1	873



SPEC B	(English)	EPBBF1	8509
Total word count - document A			0
Total word count - document B			10991
Total word count - documents A + B			10991

6/3/51 (Item 47 from file: 348)  
 DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00330079

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* SUBSTRATE ASSISTED CATALYSIS.

SUBSTRATUNTERSTUTZTE KATALYSE.

CATALYSE A EFFET DE SUBSTRAT.

PATENT ASSIGNEE:

GENENTECH, INC., (210483), 480 Point San Bruno Boulevard, San  
 Francisco, CA 94080, (US), (applicant designated states:

AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

WELLS, James, Allen, 65 Otay Avenue, San Mateo, CA 94403, (US)  
 CARTER, Paul, John, 2074 18th Avenue, San Francisco, CA 94116,

(US) LEGAL REPRESENTATIVE:

Armitage, Ian Michael et al (27761), MEWBURN ELLIS & CO. 2/3  
 Cursitor Street, London EC4A 1BQ, (GB)

PATENT (CC, No, Kind, Date): EP 308499 A1 890329 (Basic)

EP 308499 B1 930107

WO 8807578 881006

APPLICATION (CC, No, Date): EP 88903692 880330; WO 88US1078

880330 PRIORITY (CC, No, Date): US 34085 870402

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/52; C12N-009/00;

C12N-009/54; C12N-009/96; C12N-015/57;

LANGUAGE (Publication,Procedural,Application): English; English;

English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
----------------	----------	--------	------------

CLAIMS B	(English)	EPBBF1	1144
----------	-----------	--------	------

CLAIMS B	(German)	EPBBF1	1147
----------	----------	--------	------

CLAIMS B	(French)	EPBBF1	1232
----------	----------	--------	------

SPEC B	(English)	EPBBF1	12292
--------	-----------	--------	-------

Total word count - document A	0
-------------------------------	---

Total word count - document B	15815
-------------------------------	-------

Total word count - documents A + B	15815
------------------------------------	-------

6/3/52 (Item 48 from file: 348)  
 DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00325392

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* Process for the production of proteins.

Verfahren zur Herstellung von Proteinen.

Procede de production de proteines.

PATENT ASSIGNEE:

CIBA-GEIGY AG, (201300), Klybeckstrasse 141, CH-4002 Basel,  
(CH), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE) INVENTOR:

Meyhack, Bernd, Dr., Hohenweg 9, CH-4132 Magden, (CH)

Heim, Jutta, Dr., Rankackerweg 18, CH-4133 Pratteln, (CH)

Burgi, Rolf, Dr., Blasiring 140, CH-4057 Basle, (CH)

PATENT (CC, No, Kind, Date): EP 288435 A1 881026 (Basic)

EP 288435 B1 940316

APPLICATION (CC, No, Date): EP 88810234 880411;

PRIORITY (CC, No, Date): GB 8709081 870415; GB 8714059 870616; IE  
873299 871204

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-015/58; C12N-009/72;

C12P-021/00; C07K-015/14; C12N-001/16; A61K-037/02;

C12N-015/00; C12R-001/865 ABSTRACT WORD COUNT: 51

LANGUAGE (Publication,Procedural,Application): English; German;

English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	647
CLAIMS B	(German)	EPBBF1	603
CLAIMS B	(French)	EPBBF1	839
SPEC B	(English)	EPBBF1	12853
Total word count - document A			0
Total word count - document B			14942
Total word count - documents A + B			14942

6/3/53 (Item 49 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00318827

\*\*ORDER fax of complete patent from KR SourceOne. See HELP

ORDER348\*\* NANBV diagnostics and vaccines.

NANBV-Diagnostika und Vakzine.

Diagnostics et vaccins de NANBV.

PATENT ASSIGNEE:

CHIRON CORPORATION, (572530), 4560 Horton Street, Emeryville,  
California 94608, (US), (applicant designated states:

AT;BE;CH;DE;ES;FR;GR;IT;LI;LU;NL;SE)

INVENTOR:

Houghton, Michael, 1307 Greenbrook Drive, Danville California  
94526, (US) Choo, Qui-Lim, 5700 Fern Street, El Cerrito

California 94530, (US) Kuo, George, 1370 Sixth Avenue, San

Francisco California 94122, (US) LEGAL REPRESENTATIVE:

Goldin, Douglas Michael et al (31061), J.A. KEMP & CO. 14,  
South Square Gray's Inn, London WC1R 5EU, (GB)

PATENT (CC, No, Kind, Date): EP 318216 A1 890531 (Basic)

EP 318216 B1 931215

APPLICATION (CC, No, Date): EP 88310922 881118;

PRIORITY (CC, No, Date): US 122714 871118; US 139886 871230; US  
161072 880226; US 191263 880506; US 263584 881026; US 271450

881114 DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GR; IT; LI; LU;  
 NL; SE INTERNATIONAL PATENT CLASS: C12N-015/00; C12N-007/00;  
 A61K-039/29; G01N-033/576; C12Q-001/70; C12Q-001/68;  
 C07K-015/00; A61K-039/395; C12P-021/00;  
 ABSTRACT WORD COUNT: 300

LANGUAGE (Publication,Procedural,Application): English; English;  
 English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	7138
CLAIMS B	(German)	EPBBF1	5860
CLAIMS B	(French)	EPBBF1	6684
SPEC B	(English)	EPBBF1	38182
Total word count - document A			0
Total word count - document B			57864
Total word count - documents A + B			57864

6/3/54 (Item 50 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00317122

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* Adheson variants, nucleic acid encoding them and  
 compositions comprising them.  
 Adhasionsvarianten, dafur kodierende Nukleinsaure und diese  
 enthaltende Zusammensetzungen.  
 Variantes d'adhesions, acide nucleique les codant ainsi que  
 compositions les contenant.

PATENT ASSIGNEE:

GENENTECH, INC., (210480), 460 Point San Bruno Boulevard, South  
 San Francisco California 94080, (US), (applicant designated  
 states: ES;GR) INVENTOR:

Capon, Daniel J., 817 Oregon Avenue, San Mateo California  
 94402, (US) Gregory, Timothy J., 414 Pinehill Road,  
 Hillsborough California 94010, (US)

LEGAL REPRESENTATIVE:

Armitage, Ian Michael et al (27761), MEWBURN ELLIS & CO. 2/3  
 Cursitor Street, London EC4A 1BQ, (GB)

PATENT (CC, No, Kind, Date): EP 314317 A1 890503 (Basic)

APPLICATION (CC, No, Date): EP 88309194 881003;

PRIORITY (CC, No, Date): US 104329 871002; US 250785 880928

DESIGNATED STATES: ES; GR

INTERNATIONAL PATENT CLASS: C12N-015/00; C12P-021/02;

A61K-037/02; G01N-033/566

ABSTRACT WORD COUNT: 79

LANGUAGE (Publication,Procedural,Application): English; English;  
 English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1368
SPEC A	(English)	EPABF1	13972
Total word count - document A			15340

Total word count - document B 0  
Total word count - documents A + B 15340

6/3/55 (Item 51 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00316326

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* A method for culturing recombinant cells.  
Verfahren zur Zuchtung rekombinanter Zellen.  
Methode pour cultiver des cellules recombinantes.

PATENT ASSIGNEE:

GENENTECH, INC., (210480), 460 Point San Bruno Boulevard, South  
San Francisco California 94080, (US), (applicant designated  
states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Mather, Jennie P., 269 La Prenda, Millbrae California 94030,  
(US) Ullrich, Axel, Hindenbergstrasse 23, D-755 Rastaff, (DE)

LEGAL REPRESENTATIVE:

Armitage, Ian Michael et al (27761), MEWBURN ELLIS York House  
23 Kingsway, London WC2B 6HP, (GB)

PATENT (CC, No, Kind, Date): EP 307247 A2 890315 (Basic)  
EP 307247 A3 900822

EP 307247 B1 940831

APPLICATION (CC, No, Date): EP 88308386 880912;

PRIORITY (CC, No, Date): US 97472 870911

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: C12N-015/00; C12N-005/00;

ABSTRACT WORD COUNT: 58

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPBBF1	290
CLAIMS B	(English)	EPBBF1	336
CLAIMS B	(German)	EPBBF1	306
CLAIMS B	(French)	EPBBF1	373
SPEC A	(English)	EPBBF1	9933
SPEC B	(English)	EPBBF1	9910
Total word count - document A			10223
Total word count - document B			10925
Total word count - documents A + B			21148

6/3/56 (Item 52 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00314013

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Production of Kallikrein.  
Produktion von Kallikrein.

Production de kallikreine.

PATENT ASSIGNEE:

AMGEN INC., (923233), Amgen Center, 1840 Dehavilland Drive,  
Thousand Oaks, CA 91320-1789, (US), (applicant designated  
states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Lin, Fu-Kuen, 2491 Chaucer Place, Thousand Oaks, California  
91360, (US) Lu, Hsieng Sen, 3072 Chancery Place, Thousand Oaks,  
California 91362, (US)

LEGAL REPRESENTATIVE:

Brown, John David et al (28811), FORRESTER & BOEHMERT  
Franz-Joseph-Strasse 38, D-80801 Munchen, (DE)  
PATENT (CC, No, Kind, Date): EP 297913 A2 890104 (Basic)  
EP 297913 A3 900307

EP 297913 B1 950215  
APPLICATION (CC, No, Date): EP 88306039 880630;  
PRIORITY (CC, No, Date): US 68594 870630; US 210256 880627  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: C12N-015/57; C12N-009/64;  
C12N-005/00; C12Q-001/37  
ABSTRACT WORD COUNT: 53

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPBBF2	517
CLAIMS B	(English)	EPBBF2	1479
CLAIMS B	(German)	EPBBF2	1443
CLAIMS B	(French)	EPBBF2	1701
SPEC A	(English)	EPBBF2	8264
SPEC B	(English)	EPBBF2	8271
Total word count - document A			8781
Total word count - document B			12894
Total word count - documents A + B			21675

6/3/57 (Item 53 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00304583

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Chromatographic binding assay devices and methods.  
Chromatographische Bindungstesteinrichtungen und Verfahren.  
Appareil et methodes de test chromatographique de liaison. PATENT  
ASSIGNEE:

ABBOTT LABORATORIES, (225071), , Abbott Park, Illinois 60064,  
(US), (applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE) INVENTOR:  
Devereaux, Sharon Murphy, 5180 Beechwood Avenue, Gurnee, IL  
60031, (US) Wilcox, James L., 605 Smith Avenue, Lake Bluff, IL  
60044, (US) Holzman, Thomas Fredric, 1112 Tamarack Lane,  
Libertyville, IL 60048, (US) Gordon, Julian, 307 E. Sheridan  
Road, Lake Bluff, IL 60044, (US) Ching, Shanfun, 1014 Mayfair



Drive, Libertyville, IL 60048, (US) LEGAL REPRESENTATIVE:  
Modiano, Guido, Dr.-Ing. et al (40782), Modiano & Associati  
S.r.l. Via Meravigli, 16, I-20123 Milano, (IT)  
PATENT (CC, No, Kind, Date): EP 323605 A2 890712 (Basic)  
EP 323605 A3 890809  
EP 323605 B1 940126

APPLICATION (CC, No, Date): EP 88121314 881220;  
PRIORITY (CC, No, Date): US 135810 871221; US 282978 881214  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: G01N-033/558; G01N-033/543;  
ABSTRACT WORD COUNT: 95

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	933
CLAIMS B	(German)	EPBBF1	902
CLAIMS B	(French)	EPBBF1	1033
SPEC B	(English)	EPBBF1	10461
Total word count - document A			0
Total word count - document B			13329
Total word count - documents A + B			13329

6/3/58 (Item 54 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00297949

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Modified plasminogen activators.  
Modifizierte Plasminogenaktivatoren.  
Activeurs du plasminogene modifies.  
PATENT ASSIGNEE:

GRUPPO LEPETIT S.p.A., (216641), Via G. Murat 23, I-20159  
Milano, (IT), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE) INVENTOR:  
Cassani, Giovanni, 3, Via Vittadini, I-27100 Pavia, (IT)  
Blasi, Francesco, 298, Via Posillipo, I-80123 Napoli, (IT)  
Robbiati, Federico Maria, 141, Via Porpora, I-20131 Milano, (IT)  
Nolli, Marialuisa, 34, Via C. Riboldi, I-27100 Pavia, (IT) PATENT  
(CC, No, Kind, Date): EP 308716 A2 890329 (Basic)  
EP 308716 A3 890614

APPLICATION (CC, No, Date): EP 88114516 880906;  
PRIORITY (CC, No, Date): GB 8721023 870907  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: C12N-009/72; C12N-015/00;  
A61K-037/54; ABSTRACT WORD COUNT: 51  
LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	732
SPEC A	(English)	EPABF1	22992
Total word count - document A			23724

Total word count - document B 0  
Total word count - documents A + B 23724

6/3/59 (Item 55 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00295198

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Human pancreatic secretory trypsin inhibitor.  
Menschlicher pankreatischer sekretorischer Trypsininhibitor.  
Inhibitor de trypsine secrete par le pancreas humain.

PATENT ASSIGNEE:

MOCHIDA PHARMACEUTICAL CO., LTD., (469262), 7, Yotsuya 1-chome,  
Shinjuku-ku Tokyo 160, (JP), (applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;NL;SE)

INVENTOR:

Nobuhara, Masahiro, 572-10, Ohaza-Yajuro, Koshigaya-shi  
Saitama, (JP) Kanamori, Toshinori, 3556-5,  
Ohaza-Minamiogishima, Koshigaya-shi Saitama, (JP)  
Ogino, Hiromi, 10-5-502, Horikiri 8-chome, Katsushika-ku Tokyo,  
(JP) Mochida, Ei, 5-4, Komagome 2-chome, Toshima-ku Tokyo, (JP)

LEGAL REPRESENTATIVE:

Henkel, Feiler, Hanzel & Partner (100401), Mohlstrasse 37,  
D-8000 Munchen 80, (DE)

PATENT (CC, No, Kind, Date): EP 300459 A2 890125 (Basic)  
EP 300459 A3 891115

APPLICATION (CC, No, Date): EP 88111704 880720;

PRIORITY (CC, No, Date): JP 87184556 870723

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: C07K-007/10; A61K-037/64;

C12N-015/00; C12P-021/02; C12N-001/20;

ABSTRACT WORD COUNT: 142

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	677
SPEC A	(English)	EPABF1	7527
Total word count - document A			8204
Total word count - document B			0
Total word count - documents A + B			8204

6/3/60 (Item 56 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00293996

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Neuronal polypeptide and methods of production and use  
thereof. Neuronales Polypeptid und Verfahren zu seiner  
Herstellung und Verwendung. Polypeptide neuronal et methode pour

sa production et son utilisation. PATENT ASSIGNEE:  
Sloan-Kettering Institute For Cancer Research, (239590), 1275  
York Avenue, New York New York 10021, (US), (applicant  
designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)  
INVENTOR:

Dropcho, Edward J., 3937 Briar Oak Drive, Birmingham Alabama  
35243, (US) Chen, Yao-Tseng, 435 East 70th Street, Apt. 5K, New  
York New York 10021, (US)

Posner, Jerome B., 430 East 63rd Street, New York New York  
10021, (US) Old, Lloyd J., 600 West End Avenue, New York New  
York 10024, (US) LEGAL REPRESENTATIVE:

Henkel, Feiler, Hanzel & Partner (100401), Mohlstrasse 37,  
D-8000 Munchen 80, (DE)

PATENT (CC, No, Kind, Date): EP 297585 A2 890104 (Basic)  
EP 297585 A3 900523

APPLICATION (CC, No, Date): EP 88110488 880630;

PRIORITY (CC, No, Date): US 68917 870701

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-015/00; C12P-021/02;  
C12P-021/00; C07K-013/00; A61K-037/02; A61K-039/395;

ABSTRACT WORD COUNT: 50

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	361
SPEC A	(English)	EPABF1	4281
Total word count - document A			4642
Total word count - document B			0
Total word count - documents A + B			4642

6/3/61 (Item 57 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00291963

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Human cell line and triomas, antibodes, and  
transformants derived therefrom.

Humane Zellinie und davon abgeleitete Triomen,  
Antikorper und transformierte Zellen.  
Lignee de cellules humaines et triomes, anticorps et cellules  
transformees. PATENT ASSIGNEE:

CETUS CORPORATION, (229561), 1400 Fifty-Third Street,  
Emeryville California 94608, (US), (applicant designated  
states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Larrick, James William, Star Rt. Box 48, Woodside, California  
94062, (US) Senyk, George, 2319 32nd. Avenue, San Francisco,  
California 94116, (US) LEGAL REPRESENTATIVE:

Vossius & Partner (100311), Siebertstrasse 4 P.O. Box 86 07 67,  
D-8000 Munchen 86, (DE)

PATENT (CC, No, Kind, Date): EP 292965 A2 881130 (Basic)  
EP 292965 A3 900103  
APPLICATION (CC, No, Date): EP 88108421 880526;  
PRIORITY (CC, No, Date): US 54441 870527  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: C12N-005/00; C12N-015/00;  
C12P-021/00; C12P-021/00; C12R-001/91  
ABSTRACT WORD COUNT: 103

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	384
SPEC A	(English)	EPABF1	6943
Total word count - document A			7327
Total word count - document B			0
Total word count - documents A + B			7327

6/3/62 (Item 58 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00289381

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Inhibitors of angiogenin.

Angiogenininhibitoren.

Inhibiteurs d'angiogenine.

PATENT ASSIGNEE:

THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE, (227952), 17  
Quincy Street, Cambridge, MA 02138, (US), (applicant  
designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Shapiro, Robert, 181 Highland Street, Holliston, MA 01746, (US)  
Vallee, Bert L., 56 Brown Street, Brookline, MA 02146, (US)

LEGAL REPRESENTATIVE:

Bizley, Richard Edward et al (28352), HEPWORTH LAWRENCE BRYER &  
BIZLEY 2nd Floor Gate House South West Gate, Harlow, Essex

CM20 1JN, (GB) PATENT (CC, No, Kind, Date): EP 291686 A2  
881123 (Basic) EP 291686 A3

900404

EP 291686 B1 931013

APPLICATION (CC, No, Date): EP 88105781 880412;  
PRIORITY (CC, No, Date): US 38008 870414; US 177942 880405  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: A61K-037/64; A61K-037/02;  
C12N-015/00; ABSTRACT WORD COUNT: 58

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	103
CLAIMS B	(German)	EPBBF1	103
CLAIMS B	(French)	EPBBF1	137

SPEC B	(English)	EPBBF1	3475
Total word count	- document A		0
Total word count	- document B		3818
Total word count	- documents A + B		3818

6/3/63 (Item 59 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00281290

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* ENHANCEMENT OF THE CELLULAR IMMUNE RESPONSE.  
 STEIGERUNG DER ZELLULAREN IMMUNREAKTION.  
 STIMULATION DES REPONSES IMMUNITAIRES CELLULAIRES.

PATENT ASSIGNEE:

LONGENECKER, Bryan Michael, (935730), 8412-118th Street,  
 Edmonton, Alberta T6G 1T3, (CA), (applicant designated  
 states:

AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

HENNINGSSON, Carina, (935740), 8510-111 Street Apt. 1808,  
 Edmonton, Alberta T6G 1M7, (CA), (applicant designated  
 states:

AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

LONGENECKER, Bryan Michael, 8412-118th Street, Edmonton,  
 Alberta T6G 1T3, (CA)

HENNINGSSON, Carina, 8510-111 Street Apt. 1808, Edmonton,  
 Alberta T6G 1M7, (CA)

LEGAL REPRESENTATIVE:

Patentanwalte Grunecker, Kinkeldey, Stockmair & Partner  
 (100721), Maximilianstrasse 58, D-80538 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 313569 A1 890503 (Basic)

EP 313569 A1 900207

EP 313569 B1 931118

WO 8800053 880114

APPLICATION (CC, No, Date): EP 87904610 870707; WO 87US1559

870707 PRIORITY (CC, No, Date): US 883266 860708

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-035/26; A61K-037/00;

A61K-037/04; A61K-039/00; A61K-039/395; A61K-039/385;

A61K-045/05;

LANGUAGE (Publication,Procedural,Application): English; English;

English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1086
CLAIMS B	(German)	EPBBF1	1047
CLAIMS B	(French)	EPBBF1	1229
SPEC B	(English)	EPBBF1	2747
Total word count	- document A		0
Total word count	- document B		6109
Total word count	- documents A + B		6109



6/3/64 (Item 60 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00274199

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Variants of lav viruses, their dna- and protein  
components and their uses, particularly for diagnostic  
purposes and for the preparation of immunogenic  
compositi

Varianten von LAV-Viren, deren DNS- und Proteinkomponenten  
und deren Verwendung, insbesondere zu diagnostischen Zwecken  
und zur Herstellung von immunogenen Zusa

Variantes du virus LAV, leur composants d'ADN et proteiques  
ainsi que leur utilisation, en particulier a des fins  
diagnostiques et preparatives de compositions

PATENT ASSIGNEE:

INSTITUT PASTEUR, (250794), 25/28, rue du Docteur Roux, F-75015  
Paris, (FR), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Alizon, Marc, 71, rue du Cardinal Lemoine, F-75005 Paris, (FR)

Sonigo, Pierre, 23, rue Gutenberg, F-75015 Paris, (FR)

Wain-Hobson, Simon, 3, rue Jean de La Fontaine, F-78180

Montigny Les Bretonneux, (FR)

Montagnier, Luc, 21, rue de Malabry, F-92350 Le Plessis

Robinson, (FR) LEGAL REPRESENTATIVE:

Gutmann, Ernest et al (15992), S.C. Ernest Gutmann - Yves  
Plasseraud 67, boulevard Haussmann, F-75008 Paris, (FR)

PATENT (CC, No, Kind, Date): EP 253701 A1 880120 (Basic)

EP 253701 B1 921230

APPLICATION (CC, No, Date): EP 87401416 870622;

PRIORITY (CC, No, Date): EP 86401380 860623

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-015/48; C12N-007/00;

C12Q-001/70; G01N-033/569; C07K-013/00; C07K-015/00;

C12N-001/20; C12N-005/00; ABSTRACT WORD COUNT: 46

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	725
CLAIMS B	(German)	EPBBF1	684
CLAIMS B	(French)	EPBBF1	826
SPEC B	(English)	EPBBF1	11557
Total word count - document A			0
Total word count - document B			13792
Total word count - documents A + B			13792

6/3/65 (Item 61 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00265434

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Pancreatic secretory trypsin inhibitor and its  
variants produced by genetic engineering.  
Gentechnologisch hergestellter pankreatischer sekretorischer  
Trypsininhibitor oder und seine Varianten.  
Inhibiteur de trypsine secrete par le pancreas et ses variants  
produits par genie genetique.

PATENT ASSIGNEE:

BAYER AG, (200140), , D-51368 Leverkusen, (DE), (applicant  
designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;NL;SE)

INVENTOR:

Collins, John, Prof. Dr., Aegidienstrasse 5, D-3300  
Braunschweig, (DE) Blocker, Helmut, Dr., Maschplatz 13, D-3300  
Braunschweig, (DE) Frank, Ronald, Dr., Leibnitzstrasse 8,  
D-3340 Wolfenbuettel, (DE) Maywald, Friedhelm, Dr., Elzweg 32,  
D-3300 Braunschweig, (DE) Fritz, Hans, Prof. Dr.,  
Neulingerstrasse 15, D-8011 Hohenbrunn, (DE) Bruns, Wolfgang,  
Dr., Kaiser Wilhelm-Allee 37, D-5600 Wuppertal 1, (DE) PATENT  
(CC, No, Kind, Date): EP 278112 A2 880817 (Basic)

EP 278112 A3 900110

EP 278112 B1 931118

APPLICATION (CC, No, Date): EP 87119221 871224;

PRIORITY (CC, No, Date): GB 8700204 870107

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: C07K-007/10; A61K-037/64;

C12N-015/00; C12N-001/20;

ABSTRACT WORD COUNT: 69

LANGUAGE (Publication,Procedural,Application): German; German;  
German FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	406
CLAIMS B	(German)	EPBBF1	1123
CLAIMS B	(French)	EPBBF1	392
SPEC B	(German)	EPBBF1	8377
Total word count - document A			0
Total word count - document B			10298
Total word count - documents A + B			10298

6/3/66 (Item 62 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00257521

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* A cDNA coding for carcinoembryonic antigen.  
Karzinoembryonisches Antigen kodierende cDNS.  
cADN codant pour l'antigene carcinoembryonnaire.

PATENT ASSIGNEE:

MILES INC., (923417), One Mellon Center 500 Grant Str.,  
Pittsburgh, PA 15219-2502, (US), (applicant designated  
states:

AT;BE;CH;DE;ES;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

Barnett, Thomas R., 27 Jeffrey Road, East Haven, CT 06513, (US)  
Elting, James J., 5 Heatherwood Drive, Madison, CT 06443, (US)  
Kamarck, Michael E., 46 Wauwinet Trail, Guilford, CT 06437, (US)

LEGAL REPRESENTATIVE:

Danner, Klaus, Dr. et al (51861), Bayer AG Konzernverwaltung RP  
Patente Konzern, D-51368 Leverkusen, (DE)

PATENT (CC, No, Kind, Date): EP 263933 A1 880420 (Basic)  
EP 263933 B1 931020

APPLICATION (CC, No, Date): EP 87111168 870803;

PRIORITY (CC, No, Date): US 896361 860813; US 16683 870219; US

60031 870619 DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; IT;

LI; LU; NL; SE INTERNATIONAL PATENT CLASS: C12N-015/12;

C07K-013/00; A61K-037/02; G01N-033/574; C12Q-001/68;

C12N-005/10;

ABSTRACT WORD COUNT: 87

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1417
CLAIMS B	(German)	EPBBF1	782
CLAIMS B	(French)	EPBBF1	918
SPEC B	(English)	EPBBF1	9794
Total word count - document A			0
Total word count - document B			12911
Total word count - documents A + B			12911

6/3/67 (Item 63 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00251041

\*\*ORDER fax of complete patent from KR SourceOne. See HELP

ORDER348\*\* Serine protease inhibitors.

Serinprotease-Hemmungsstoffe.

Inhibiteurs de serine proteases.

PATENT ASSIGNEE:

Monsanto Company, (201270), Patent Department 800 North  
Lindbergh Boulevard, St. Louis Missouri 63167, (US),

(applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Glover, George Irvin, 22 Wind Rush Creek West, Creve Coeur  
Missouri 63141, (US)

Schasteen, Charles Steven, 7557 Cornell, University City  
Missouri 63130, (US)

LEGAL REPRESENTATIVE:

Ernst, Hubert et al (465), Monsanto Services International  
S.A., Patent Department, Avenue de Tervuren 270-272, Letter

Box No. 21, B-1150 Brussels, (BE)

PATENT (CC, No, Kind, Date): EP 238473 A2 870923 (Basic)

EP 238473 A3 890607  
APPLICATION (CC, No, Date): EP 87870035 870317;  
PRIORITY (CC, No, Date): US 840810 860318; US 6725 870206  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: C07K-007/00; C07K-007/06;  
C07K-007/10; A61K-037/64;  
ABSTRACT WORD COUNT: 125

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	600
SPEC A	(English)	EPABF1	10744
Total word count - document A			11344
Total word count - document B			0
Total word count - documents A + B			11344

6/3/68 (Item 64 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00251010

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Human preproinsulin-like growth factor I.  
Menschlicher prapropinsulinahnlicher Wachstumsfaktor I.  
Facteur de croissance humain I analogue a la pre-pro insuline.  
PATENT ASSIGNEE:

WASHINGTON UNIVERSITY, (645440), Lindell and Skinker  
Boulevards, St. Louis, Missouri 63130, (US), (applicant  
designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)  
INVENTOR:

Krivi, Gwen Grabowski, 9400 Harvest Court, St. Louis Missouri  
63132, (US) Rotwein, Peter Scott, 19 N. Taylor, St. Louis  
Missouri 63110, (US) LEGAL REPRESENTATIVE:

Ernst, Hubert G. et al (467), Monsanto Services International  
S.A. Letter Box 21 Avenue de Tervuren 270-272, B-1150  
Brussels, (BE) PATENT (CC, No, Kind, Date): EP 229750 A2  
870722 (Basic) EP 229750 A3  
891025

EP 229750 B1 940413  
APPLICATION (CC, No, Date): EP 87870001 870106;  
PRIORITY (CC, No, Date): US 816662 860107; US 929671 861120  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: C12N-015/00; C12P-021/02;  
A61K-037/02; ABSTRACT WORD COUNT: 86

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	472
CLAIMS B	(German)	EPBBF1	433
CLAIMS B	(French)	EPBBF1	556
SPEC B	(English)	EPBBF1	10507

Total word count - document A 0  
Total word count - document B 11968  
Total word count - documents A + B 11968

6/3/69 (Item 65 from file: 348)  
DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00249293

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Procedure for exposing an epitope within a protein  
possessing a distinct polypeptide structure, and the products  
obtained.

Verfahren zum Exponieren eines Epitops in einem Protein, das eine  
bestimmte Polypeptidstruktur besitzt, und die erhaltenen  
Produkte. Procédé pour exposer un epitope au sein d'une  
proteine présentant une structure polypeptidique distincte et  
produits obtenus. PATENT ASSIGNEE:

INSTITUT PASTEUR, (250790), 25-28, rue du Docteur Roux, F-75724  
Paris Cedex 15, (FR), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), (428833),  
15, Quai Anatole France, F-75700 Paris Cedex 07, (FR),  
(applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Hofnung, Maurice, 19 bis, rue Bague, F-75015 Paris, (FR)  
Charbit, Alain, 97 avenue de Verdun, F-92130 Issy-les-Moulineaux,  
(FR) Boulain, Jean-Claude, 258, rue de Paris, F-91120

Palaiseau, (FR) LEGAL REPRESENTATIVE:

Gutmann, Ernest (15992), S.C. Ernest Gutmann - Yves Plasseraud  
67, boulevard Haussmann, F-75008 Paris, (FR)

PATENT (CC, No, Kind, Date): EP 242243 A1 871021 (Basic)

EP 242243 B1 930623

APPLICATION (CC, No, Date): EP 87400504 870306;

PRIORITY (CC, No, Date): FR 863322 860307; US 13796 870212

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-015/62; C12N-001/20;

C07K-015/04; G01N-033/53; C12N-001/20; C12R-001/19

ABSTRACT WORD COUNT: 87

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1556
CLAIMS B	(German)	EPBBF1	1428
CLAIMS B	(French)	EPBBF1	1580
SPEC B	(English)	EPBBF1	6965
Total word count - document A			0
Total word count - document B			11529
Total word count - documents A + B			11529



6/3/70 (Item 66 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00247603

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Human pancreatic elastase I.

Menschliche Pankreaselastase I.

Elastase I pancreatique humaine.

PATENT ASSIGNEE:

Sankyo Company Limited, (204881), 5-1 Nihonbashi Honcho 3-chome  
Chuo-ku, Tokyo, (JP), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

Takiguchi, Yo Sankyo Bio-Science, Research Laboratories No.  
2-58 1-chome Hiromachi, Shinagawa-ku Tokyo 140, (JP)

Tani, Tokio Sankyo Bio-Science, Research Laboratories No. 2-58  
1-chome Hiromachi, Shinagawa-ku Tokyo 140, (JP)

Ohmine, Toshinori Sankyo Bio-Science, Research Laboratories No.  
2-58 1-chome Hiromachi, Shinagawa-ku Tokyo 140, (JP)

Furukawa, Hidehiko Sankyo Bio-Science, Research Laboratories  
No. 2-58 1-chome Hiromachi, Shinagawa-ku Tokyo 140, (JP)

Kawashima, Ichiro Sankyo Bio-Science, Research Laboratories No.  
2-58 1-chome Hiromachi, Shinagawa-ku Tokyo 140, (JP)

LEGAL REPRESENTATIVE:

Gibson, Christian John Robert et al (30951), MARKS & CLERK  
57/60 Lincoln's Inn Fields, London WC2A 3LS, (GB)

PATENT (CC, No, Kind, Date): EP 244189 A2 871104 (Basic)

EP 244189 A3 890208

EP 244189 B1 930825

APPLICATION (CC, No, Date): EP 87303711 870427;

PRIORITY (CC, No, Date): JP 8697259 860426

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/00; C12N-009/66;

C07H-021/04; C12N-001/00; C12P-021/02; A61K-037/547;

ABSTRACT WORD COUNT: 16

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	337
CLAIMS B	(German)	EPBBF1	310
CLAIMS B	(French)	EPBBF1	365
SPEC B	(English)	EPBBF1	6459
Total word count - document A			0
Total word count - document B			7471
Total word count - documents A + B			7471

6/3/71 (Item 67 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00246856

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Antigens, antibodies and methods for the  
identification of metastatic human tumors, and cell lines for  
producing said antibodies.

Antigene, Antikörper und Verfahren zur Identifizierung  
humaner metastatischer Tumoren und Zelllinien zur Herstellung  
dieser Antikörper. Antigènes, anticorps et méthodes  
d'identification de tumeurs humaines métastatiques et  
lignées de cellules pour la production de ces  
anticorps.

PATENT ASSIGNEE:

BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM, (266341),  
Office of General Council, 201 West 7th Street, Austin, Texas  
78701, (US), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;IT;LI;LU;NL;SE) INVENTOR:

Nicolson, Garth L., 2611 Valley Manor Drive, Kingwood, TX  
77339, (US) North, Susan M., 10202 Forum Park Drive, Apt. 100,  
Houston, TX 77036, (US)

Steck, Peter A., 1800 Holcombe, Apt. 209, Houston, TX 77030,  
(US) LEGAL REPRESENTATIVE:

Allard, Susan Joyce et al (27611), BOULT, WADE & TENNANT 27  
Furnival Street, London EC4A 1PQ, (GB)

PATENT (CC, No, Kind, Date): EP 240341 A2 871007 (Basic)

EP 240341 A3 890719

EP 240341 B1 940511

APPLICATION (CC, No, Date): EP 87302848 870401;

PRIORITY (CC, No, Date): US 846938 860401

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C07K-015/14; C07K-015/06;

C07K-015/00; C12P-021/00; C12N-005/00; C12N-015/00;

G01N-033/574; G01N-033/577; C12P-021/00; C12R-001/91

ABSTRACT WORD COUNT: 79

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	775
CLAIMS B	(German)	EPBBF1	747
CLAIMS B	(French)	EPBBF1	871
SPEC B	(English)	EPBBF1	13679
Total word count - document A			0
Total word count - document B			16072
Total word count - documents A + B			16072

6/3/72 (Item 68 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00245706

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Amino acid modified prourokinase and method of  
preparation. In Aminosäuren modifizierte Prourokinase und Methode  
zu ihrer Herstellung. Prourokinase modifiée dans des acides

amines, et methode de preparation. PATENT ASSIGNEE:

COLLABORATIVE RESEARCH INC., (464552), Two Oak Park, Bedford  
Massachusetts 01730, (US), (applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Vovis, Gerald F., 360 Bacon Street, Waltham Massachusetts  
02154, (US) Mao, Jen-I, 213 Follen Road, Lexington

Massachusetts 02173, (US) LEGAL REPRESENTATIVE:

Shipley, Warwick Grenville Michael et al , VANNER, SHIPLEY &  
CO. 368 City Road, London EC1V 2QA, (GB)

PATENT (CC, No, Kind, Date): EP 236040 A2 870909 (Basic)

EP 236040 A3 890503

APPLICATION (CC, No, Date): EP 87301567 870224;

PRIORITY (CC, No, Date): US 833179 860226; US 12023 870219

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: C12N-009/72; C12N-015/00;

ABSTRACT WORD COUNT: 52

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	367
SPEC A	(English)	EPABF1	6524
Total word count - document A			6891
Total word count - document B			0
Total word count - documents A + B			6891

6/3/73 (Item 69 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00244645

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Production of human erythropoietin.  
Herstellung von menschlichem Erythropoietin.  
Production d'erythropoietine humaine.

PATENT ASSIGNEE:

SUMITOMO CHEMICAL COMPANY, LIMITED, (214340), Kitahama 4-chome  
5-33, Chuo-ku Osaka 541, (JP), (applicant designated states:  
CH;DE;FR;GB;LI) INVENTOR:

Yanagi, Hideki, 14-26, Hanayashiki-Matsugaoka, Takarazuka-shi  
Hyogo 665, (JP)

Ogawa, Ikuzo, 2-10-3-355, Sonehigashimachi, Toyonaka-shi Osaka  
561, (JP) Okamoto, Minoru, 15-10-204, Kusunokicho, Ashiya-shi  
Hyogo 659, (JP) Hozumi, Tatsunobu, 2-10-3-315,  
Sonehigashimachi, Toyonaka-shi Osaka 561, (JP)

Soga, Ayuko, 2-57-403, Hamamatsubaracho, Nishinomiya-shi Hyogo  
662, (JP) Yoshima, Tadahiko, 2-10-3-357, Sonehigashimachi,  
Toyonaka-shi Osaka 561, (JP)

Tsutsumi, Masahiro, 1295-110, Shidehara, Sanda-shi Hyogo  
669-13, (JP) LEGAL REPRESENTATIVE:

Cresswell, Thomas Anthony et al (50352), J.A. Kemp & Co. 14  
South Square Gray's Inn, London WC1R 5EU, (GB)

PATENT (CC, No, Kind, Date): EP 232034 A2 870812 (Basic)  
EP 232034 A3 880113

EP 232034 B1 920708

APPLICATION (CC, No, Date): EP 87300399 870119;

PRIORITY (CC, No, Date): JP 8612868 860123

DESIGNATED STATES: CH; DE; FR; GB; LI

INTERNATIONAL PATENT CLASS: C12N-015/16; C12N-015/63;

ABSTRACT WORD COUNT: 46

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	65
CLAIMS B	(German)	EPBBF1	72
CLAIMS B	(French)	EPBBF1	76
SPEC B	(English)	EPBBF1	3707
Total word count - document A			0
Total word count - document B			3920
Total word count - documents A + B			3920

6/3/74 (Item 70 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00238210

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Selective immunoassay for pro-urokinase and urokinase.  
Selektiver Immunoassay fur Pro-Urokinase und Urokinase.  
Essai immunologique selectif pour pro-urokinase et urokinase.  
PATENT ASSIGNEE:

GRUPPO LEPETIT S.p.A., (216641), Via G. Murat 23, I-20159  
Milano, (IT), (applicant designated states:  
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE) INVENTOR:

Corti, Angelo, 2, Via Mozzi, I-24100 Bergamo, (IT)  
Nolli, Marialuisa, 15, Via Cavallini, I-27100 Pavia, (IT)  
Cassani, Giovanni, 3, Via Vittadini, I-27100 Pavia, (IT)  
Parenti, Francesco, 24, Via Benvenuto Cellini, I-20020 Lainate  
(Milano), (IT)

LEGAL REPRESENTATIVE:

Sgarbi, Renato et al (41021), GRUPPO LEPETIT S.p.A. Patent and  
Trademark Department Via Roberto Lepetit, 34, I-21040  
Gerenzano (Varese), (IT) PATENT (CC, No, Kind, Date): EP 248144  
A2 871209 (Basic) EP 248144 A3  
890308

EP 248144 B1 921021

APPLICATION (CC, No, Date): EP 87102122 870214;

PRIORITY (CC, No, Date): GB 8604851 860227

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;

NL; SE INTERNATIONAL PATENT CLASS: G01N-033/573; G01N-033/577;

G01N-033/543 ABSTRACT WORD COUNT: 78

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	573
CLAIMS B	(German)	EPBBF1	606
CLAIMS B	(French)	EPBBF1	626
SPEC B	(English)	EPBBF1	5778
Total word count - document A			0
Total word count - document B			7583
Total word count - documents A + B			7583

6/3/75 (Item 71 from file: 348)  
 DIALOG(R) File 348:EUROPEAN PATENTS FULLTEXT  
 (c) 1997 EPO. All rts. reserv.

00230919

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
 ORDER348\*\* DNA SEQUENCE ENCODING A HIRUDIN-LIKE PROTEIN AND  
 PROCESS FOR PREPARING SUCH PROTEIN.  
 FUR EIN HIRUDINAHNLICHES PROTEIN KODIERENDE DNS-SEQUENZ UND  
 VERFAHREN ZUR HERSTELLUNG EINES SOLCHEN PROTEINS.  
 SEQUENCE D'ADN CODANT UNE PROTEINE SEMBLABLE A L'HIRUDIN ET  
 PROCEDE DE PREPARATION DE CETTE PROTEINE.  
 PATENT ASSIGNEE:

CIBA-GEIGY AG, (201300), Klybeckstrasse 141, CH-4002 Basel,  
 (CH), (applicant designated states:  
 AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE) UCP GEN-PHARMA AG, (1074800),  
 Solothurnstrasse 24, CH-3422 Kirchberg, (CH), (applicant  
 designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE) INVENTOR:  
 FORTKAMP, Elke, Oberer Rainweg 29, W-6900 Heidelberg, (DE)  
 RIEGER, Michael, Angelhofweg 39, W-6916 Wilhelmsfeld, (DE)  
 SOMMER, Reinhold, Furtwanglerstr. 39, W-6900 Heidelberg, (DE)  
 FINK, Ernest, Stellhorner Strasse 1, W-2910  
 Westerstede-Giesselhorst, (DE)

LEGAL REPRESENTATIVE:

Vossius & Partner, Siebertstrasse 4 P.O. Box 86 07 67, D-8000  
 Munchen 86, (DE)

PATENT (CC, No, Kind, Date): EP 236330 A1 870916 (Basic)  
 EP 236330 B1 930623

WO 8603517 860619  
 APPLICATION (CC, No, Date): EP 86900122 851212; WO 85EP698  
 851212 PRIORITY (CC, No, Date): DE 3445517 841213  
 DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE  
 INTERNATIONAL PATENT CLASS: C07K-015/00; C12N-001/20;  
 C12R-001/19; LANGUAGE (Publication,Procedural,Application):  
 English; English; English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	197
CLAIMS B	(German)	EPBBF1	151
CLAIMS B	(French)	EPBBF1	210
SPEC B	(English)	EPBBF1	4485
Total word count - document A			0
Total word count - document B			5043
Total word count - documents A + B			5043



6/3/76 (Item 72 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00224049

\*\*ORDER fax of complete patent from KR SourceOne. See HELP

ORDER348\*\* Mammalian interleukin-4.

Saugetier-Interleukin-4.

Interleukine-4 mammalienne.

PATENT ASSIGNEE:

Schering Biotech Corporation, (636051), 901 California Avenue,  
Palo Alto California 94304-1104, (US), (applicant designated  
states: ES;GR) INVENTOR:

Lee, Frank, 212 Rinconada Avenue, Palo Alto California 94301,  
(US) Yokota, Takashi, 890 Colorado Avenue, Palo Alto California  
94303, (US) Arai, Ken-ichi, 638 Georgia Avenue, Palo Alto  
California 94306, (US) Mosmann, Timothy, 69 Lloyd Drive,  
Atherton California 94025, (US) Rennick, Donna, 601 Almond  
Avenue, Los Altos California 94022, (US) Smith, Craig, 350  
Franklin Street, Mountain View California 94041, (US) LEGAL  
REPRESENTATIVE:

Ritter, Stephen David et al , Mathys & Squire 10 Fleet Street,  
London EC4Y 1AY, (GB)

PATENT (CC, No, Kind, Date): EP 230107 A1 870729 (Basic)

APPLICATION (CC, No, Date): EP 86309041 861119;

PRIORITY (CC, No, Date): US 799668 851119; US 799669 851119; US  
843958 860325; US 881553 860703; US 908215 860917

DESIGNATED STATES: ES; GR

INTERNATIONAL PATENT CLASS: C07K-015/00; C07K-013/00;  
C12N-015/00; C12P-021/00; A61K-037/02;

ABSTRACT WORD COUNT: 62

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1924
SPEC A	(English)	EPABF1	27101
Total word count - document A			29025
Total word count - document B			0
Total word count - documents A + B			29025

6/3/77 (Item 73 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00220617

\*\*ORDER fax of complete patent from KR SourceOne. See HELP

ORDER348\*\* Monoclonal antibodies to human plasma  
prekallikrein and methods of preparing and using same.

Monoklonale Antikörper gegen menschliches

Plasma-Prekallikrein und Verfahren zu ihrer Herstellung und  
Verwendung.

Anticorps monoclonaux contre la prekallikreine de plasma humain

et methodes pour leur preparation et leur utilisation.

PATENT ASSIGNEE:

Temple University of the Commonwealth System of Higher Education, (512212), Broad Street and Montgomery Avenue, Philadelphia PA 19122, (US), (applicant designated states: DE;FR;GB;IT)

INVENTOR:

Veloso, Dulce C., 6200 Wayne Avenue, Apt. C-311, Philadelphia, PA 19144, (US)

Colman, Robert W., 9 Rose Valley Road, Moylan, PA 19065, (US)  
LEGAL REPRESENTATIVE:

Ackroyd, Robert et al (52395), W.P. THOMPSON & CO. Eastcheap House Central Approach, Letchworth, Hertfordshire SG6 3DS, (GB) PATENT (CC, No, Kind, Date): EP 210029 A2 870128 (Basic)  
EP 210029 A3 890125  
EP 210029 B1 940601

APPLICATION (CC, No, Date): EP 86305373 860714;

PRIORITY (CC, No, Date): US 754800 850712; US 883218 860708

DESIGNATED STATES: DE; FR; GB; IT

INTERNATIONAL PATENT CLASS: C07K-015/00; C12P-021/00;  
C12N-015/00; C12N-005/00; G01N-033/573; G01N-033/577;  
C12P-021/00; C12R-001/91 ABSTRACT WORD COUNT: 74

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPBBF1	1029
CLAIMS B	(English)	EPBBF1	945
CLAIMS B	(German)	EPBBF1	947
CLAIMS B	(French)	EPBBF1	1096
SPEC A	(English)	EPBBF1	7500
SPEC B	(English)	EPBBF1	7444
Total word count - document A			8529
Total word count - document B			10432
Total word count - documents A + B			18961

6/3/78 (Item 74 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00215065

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Antigenic proteins and vaccines containing them  
for prevention of coccidiosis.

Antigene Proteine und diese enthaltende Impfstoffe zur  
Verhutung von Kokzidiose.

Proteines antigenes et vaccins les contenant pour prevention de  
coccidiose. PATENT ASSIGNEE:

SOLVAY, (200422), Rue du Prince Albert, 33, B-1050 Bruxelles,  
(BE), (applicant designated states:

AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE) INVENTOR:

Newman, Karel Z., Jr., 800 West Fifth Avenue North, Clear Lake  
Iowa 50428 , (US)

Gore, Thomas C., 1106 Hildreth Street, Charles City Iowa 50616,  
(US) Tedesco, John L., 5, Novella Drive, St. Peters Missouri  
63376, (US) Petersen, Gary R., 210 2nd Avenue, Charles City  
Iowa 50616, (US) Brothers, Virginia M., 988 Peralta Avenue,  
Albany California 94706, (US) Files, James G., 1911 Lyon  
Avenue, Belmont California 94002, (US) Paul, Leland S., 2390  
Kings Point Road, Island Lake, Il. 60042, (US) Chang, Ray-Jen,  
602 St. Croix Lane, Foster City California 94404, (US) Andrews,  
William H., 1210 Geraldine Way Apt. 201, Belmont California  
94002, (US)

Kuhn, Irene, 625, Ashbury Apt. 12, San Francisco California  
94002, (US) McCaman, Michael, 746 Cherry Avenue, San Bruno  
California 94066, (US) Sias, Stacey R., 37 Carlson Court, San  
Anselmo California 94960, (US) Nordgren, Robert M., Rural Route  
1, Charles City, Iowa 50616, (US) Dragon, Elizabeth A., 42 Park  
Lane Drive, Orinda California 94563, (US) LEGAL REPRESENTATIVE:

Lechien, Monique et al (60442), Solvay Departement de la  
Propriete Industrielle Rue de Ransbeek, 310, B-1120  
Bruxelles, (BE) PATENT (CC, No, Kind, Date): EP 231537 A2  
870812 (Basic) EP 231537 A3  
880210

EP 231537 B1 920311

APPLICATION (CC, No, Date): EP 86202087 861124;  
PRIORITY (CC, No, Date): US 805301 851203; US 805824 851206; US  
807497 851211; US 808013 851211  
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU;  
NL; SE INTERNATIONAL PATENT CLASS: C12N-015/30; C12N-015/62;  
C12P-021/00; A61K-039/012;  
ABSTRACT WORD COUNT: 141

LANGUAGE (Publication,Procedural,Application): English; English;  
English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	3704
CLAIMS B	(German)	EPBBF1	1389
CLAIMS B	(French)	EPBBF1	1615
SPEC B	(English)	EPBBF1	20493
Total word count - document A			0
Total word count - document B			27201
Total word count - documents A + B			27201

6/3/79 (Item 75 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT  
(c) 1997 EPO. All rts. reserv.

00181663

\*\*ORDER fax of complete patent from KR SourceOne. See HELP  
ORDER348\*\* Gram-negative bacterial endotoxin blocking monoclonal  
antibodies and cells producing the same and formulations  
containing the same, and the production of all th  
Endotoxin von Gram-negativ-Bakterien blockierende monoklonale  
Antikorper, Zellen die diese produzieren, Zubereitungen  
die diese enthalten und Verfahren zur Hers

Anticorps monoclonaux bloquant une endotoxine de bacteries gram-negatives, cellules les produisant, formulations les contenant et la production de ces corps.

PATENT ASSIGNEE:

CETUS CORPORATION, (229561), 1400 Fifty-Third Street, Emeryville California 94608, (US), (applicant designated states:

AT;BE;CH;DE;FR;GB;IT;LI;NL;SE)

INVENTOR:

Larrick, James W., Star Route Box 48, Woodside California 94062, (US) Raubitschek, Andrew A., 4301 Jones Bridge Road, Bethesda Maryland 20814, (US)

LEGAL REPRESENTATIVE:

Bizley, Richard Edward et al (28352), HEPWORTH LAWRENCE BRYER & BIZLEY 2nd Floor Gate House South West Gate, Harlow, Essex

CM20 1JN, (GB) PATENT (CC, No, Kind, Date): EP 174204 A2

860312 (Basic) EP 174204 A3

860618

EP 174204 B1 911121

APPLICATION (CC, No, Date): EP 85306329 850905;

PRIORITY (CC, No, Date): US 647611 840905; US 727821 850426

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/40; C12P-021/08;

C12N-005/00; ABSTRACT WORD COUNT: 81

LANGUAGE (Publication,Procedural,Application): English; English; English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	386
CLAIMS B	(German)	EPBBF1	365
CLAIMS B	(French)	EPBBF1	430
SPEC B	(English)	EPBBF1	6063
Total word count - document A			0
Total word count - document B			7244
Total word count - documents A + B			7244

6/3/80 (Item 76 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS FULLTEXT

(c) 1997 EPO. All rts. reserv.

00179185

\*\*ORDER fax of complete patent from KR SourceOne. See HELP ORDER348\*\* Lymphotoxin, nucleic acid encoding it, vectors incorporating the nucleic acid and cells transformed therewith, methods of obtaining lymphotoxin, and lymphotoxin Lymphotoxin, dafur kodierende Nukleinsaeure, die Nukleinsaeure enthaltenden Vektoren und damit transformierte Zellen, Verfahren zum Erhalten von Lymphotoxin und L Lymphotoxine, acide nucleique codant pour celle-ci, vecteurs incorporant cet acide nucleique et cellules transformees avec ceux-ci, procede pour obtenir une lym

PATENT ASSIGNEE:

GENENTECH, INC., (210480), 460 Point San Bruno Boulevard, South

San Francisco California 94080, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

Aggarwal, Bharat Bhushan, 324 Del Rosa Way, San Mateo California 94403, (US)

Gray, Patrick William, 219 San Fernando Way, San Francisco California 94127, (US)

Bringman, Timothy Scott, 6571 Liggett Drive, Oakland California 94611, (US)

Nedwin, Glenn Evan, 429 S. Hoop Pole Road, Guilford Connecticut 06437, (US)

LEGAL REPRESENTATIVE:

Armitage, Ian Michael et al (27761), MEWBURN ELLIS & CO. 2 Cursitor Street, London EC4A 1BQ, (GB)

PATENT (CC, No, Kind, Date): EP 164965 A2 851218 (Basic)

EP 164965 A3 880406

EP 164965 B1 930929

APPLICATION (CC, No, Date): EP 85303818 850530;

PRIORITY (CC, No, Date): US 616503 840531; US 616502 840531; US 732312 850509

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12P-021/02; C12N-015/00;

C07K-015/00; G01N-033/532;

ABSTRACT WORD COUNT: 98

LANGUAGE (Publication,Procedural,Application): English; English; English FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	2540
CLAIMS B	(German)	EPBBF1	2297
CLAIMS B	(French)	EPBBF1	2992
SPEC B	(English)	EPBBF1	14680
Total word count - document A			0
Total word count - document B			22509
Total word count - documents A + B			22509

6/3/81 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 1997 Derwent Publ Ltd. All rts. reserv.

159484 DBA Accession No.: 94-02035

Characterization of antisense binding properties of peptide nucleotide acids by capillary gel electrophoresis - examination of peptide nucleic acid binding to oligonucleotide

AUTHOR: Rose D J

CORPORATE AFFILIATE: Glaxo

CORPORATE SOURCE: Bioanalytical and Structural Chemistry

Department, Glaxo Research Institute, 5 Moore Drive, Research Triangle Park, North Carolina 27709, USA.

JOURNAL: Anal.Chem. (65, 24, 3545-49) 1993

CODEN: ANCHAM

LANGUAGE: English



6/3/82 (Item 2 from file: 357)  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 1997 Derwent Publ Ltd. All rts. reserv.

081524 DBA Accession No.: 88-12373  
Capillary electrophoresis - mechanics of the technique and  
potential application in laboratory and clinic  
AUTHOR: Knight P  
CORPORATE SOURCE: (Pub. Address) Nature Publishing Company, 15  
East 26th Street, New York, NY 10010, USA.  
JOURNAL: Bio/Technology (6, 10, 1226-27) 1988  
CODEN: BTCHDA  
LANGUAGE: English

6/3/83 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 1997 Elsevier Science B.V. All rts. reserv.

9452724 EMBASE No: 95022380  
Purification and characterization of two forms of  
beta-D-galactosidase from rat epididymal luminal fluid:  
Evidence for their role in the modification of sperm plasma  
membrane glycoprotein(s)  
Tulsiani D.R.P.; Skudlarek M.D.; Araki Y.; Orgebin-Crist M.-C.  
Ctr. Reproductive Biology Research, Dept. Obstetrics and  
Gynecology, Vanderbilt Univ. School of Medicine, Nashville, TN  
37232-2633 USA BIOCHEM. J. (United Kingdom) , 1995, 305/1  
(41-50) CODEN: BIJOA ISSN: 0264-6021  
LANGUAGES: English SUMMARY LANGUAGES: English

6/3/84 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 1997 Elsevier Science B.V. All rts. reserv.

8450147 EMBASE No: 92126086  
Recognition of collagen by fibroblasts through cell surface  
glycoproteins reactive with Phaseolus vulgaris agglutinin  
Asaga H.; Yoshizato K.  
Japan  
J. CELL SCIENCE (United Kingdom) , 1992, 101/3 (625-633)  
CODEN: JNCSA ISSN: 0021-9533  
LANGUAGES: English SUMMARY LANGUAGES: English

6/3/85 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 1997 Elsevier Science B.V. All rts. reserv.

6216066 EMBASE No: 86211129  
Lectin binding glycoproteins in human melanoma cell lines  
with high or low tumorigenicity

Berthier-Vergnes O.; Reano A.; Dore J.-F.  
Laboratoire d'Immunologie et de Cancerologie Experimentale  
INSERM U. 218, Centre Leon Berard, 69373 Lyon Cedex 08 FRANCE  
INT. J. CANCER (USA) , 1986, 37/5 (747-751) CODEN: IJCNA  
LANGUAGES: ENGLISH

6/3/86 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 1997 Elsevier Science B.V. All rts. reserv.

5615073 EMBASE No: 84110739  
A 61,000-dalton truncated large T-antigen is uniformly  
expressed in hamster cells transformed by polyomavirus  
Rey-Bellet V.; Turler H.  
Department of Molecular Biology, University of Geneva,  
1211 Geneva SWITZERLAND  
J. VIROL. (USA) , 1984, 50/2 (587-597) CODEN: JOVIA  
LANGUAGES: ENGLISH

6/3/87 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 1997 Elsevier Science B.V. All rts. reserv.

544391 EMBASE No: 76129026  
Synthesis of reovirus specific polypeptides in cells  
pretreated with cycloheximide  
Lau R.Y.; Van Alstyne D.; Berckmans R.; Graham A.F.  
Dept. Biochem., McGill Univ., Montreal CANADA  
J.VIROL. (BALT.) (USA) , 1975, 16/3 (470-478) CODEN: JOVIA  
LANGUAGES: ENGLISH

6/3/88 (Item 1 from file: 5)  
DIALOG(R)File 5:BIOSIS PREVIEWS(R)  
(c) 1997 BIOSIS. All rts. reserv.

11896049 BIOSIS Number: 98496049  
Purification, characterization and substrate specificity of rat  
pancreatic elastase II  
Szilagyi C M; Sarfati P; Pradayrol L; Morisset J  
Dep. Biol., Fac. Sci., Univ. Sherbrooke, Sherbrooke, PQ J1K  
2R1, Canada Biochimica et Biophysica Acta 1251 (1). 1995.  
55-65.  
Full Journal Title: Biochimica et Biophysica Acta  
ISSN: 0006-3002  
Language: ENGLISH  
Print Number: Biological Abstracts Vol. 100 Iss. 010 Ref.  
146906

6/3/89 (Item 2 from file: 5)  
DIALOG(R)File 5:BIOSIS PREVIEWS(R)  
(c) 1997 BIOSIS. All rts. reserv.

7028220 BIOSIS Number: 87088741  
CHARACTERIZATION OF A NEW SEROTYPE OF INFECTIOUS PANCREATIC  
NECROSIS VIRUS ISOLATED FROM ATLANTIC SALMON  
CHRISTIE K E; HAVARSTEIN L S; DJUPVIK H O; NESS S; ENDRESEN C  
UNIVERSITETET I BERGEN, FELLESLABORATORIUM BIOTEKNOLOGI, POSTBOKS  
3152, ARSTAD, N-5001 BERGEN, NORWAY.  
ARCH VIROL 103 (3-4). 1988. 167-178. CODEN: ARVID  
Full Journal Title: Archives of Virology  
Language: ENGLISH

6/3/90 (Item 3 from file: 5)  
DIALOG(R)File 5:BIOSIS PREVIEWS(R)  
(c) 1997 BIOSIS. All rts. reserv.

5417561 BIOSIS Number: 82062364  
CHARACTERIZATION OF ANTIGEN DETECTED ON RAT THYMUS  
SUBPOPULATION AND ITS APPLICATION TO ANALYSIS OF IN-VITRO  
INTRATHYMIC T CELL DIFFERENTIATION IWAKI H; MATSUURA A; ISHII Y  
DEP. PATHOL., SAPPORO MED. COLL.  
SAPPORO MED J 55 (3). 1986. 251-268. CODEN: SIZSA  
Full Journal Title: Sapporo Medical Journal  
Language: JAPANESE

6/3/91 (Item 1 from file: 434)  
DIALOG(R)File 434:Scisearch(R) Cited Ref Sci  
(c) 1997 Inst for Sci Info. All rts. reserv.

13720718 Genuine Article#: QK518 No. References: 34  
Title: RECOGNITION OF DNA-SEQUENCES BY STRAND REPLACEMENT WITH  
POLYAMINO-OLIGONUCLEOTIDES  
Author(s): SCHMID N; BEHR JP  
Corporate Source: FAC PHARM STRASBOURG, CNRS, CHIM GENET LAB, BP  
24/F-67401 ILLKIRCH GRAFFENS//FRANCE/; FAC PHARM  
STRASBOURG, CNRS, CHIM GENET LAB/F-67401 ILLKIRCH  
GRAFFENS//FRANCE/  
Journal: TETRAHEDRON LETTERS, 1995, V36, N9 (FEB 27), P1447-1450  
ISSN: 0040-4039  
Language: ENGLISH Document Type: ARTICLE (Abstract Available)

Set	Items	Description
S1	10921	PNA OR PEPTIDE(2W)NUCLEIC
S2	9555	S1 NOT (PY=1997 OR PY=1996)
S3	685	S2 AND (HYBRID OR HYBRIDS OR COMPLEMENT? OR
HYBRIDIZ?) S4	350346	AGAROSE OR POLYACRYLAMID? OR
CAPILLAR?(2W)ELECTROPHOR? S5	97	S3 AND S4
S6	91	RD (unique items)